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1. Introduction 
 
Diabetes is a metabolic disorder of multiple causes characterized by chronic 
hyperglycemia and disorders of carbohydrate, fat and protein metabolism associated 
with defect in insulin secretion (type 1) or inability of the secreted insulin for its 
action (type 2).  
Diabetes mellitus is one of the major health concerns in developing as well as 
developed countries. The number of people affected with diabetes world wide is 
projected to increase from 171 million in the year 2000 to 366 million by year 2030 
world wide 1. In Germany, about 7 million people are known to have manifested 
diabetes mellitus, 2 to 3 million are thought to have undetected disease and about 10 
million people are diagnosed having impaired glucose tolerance. It is suspected that 
in the near future every third person in German population of age group over 65 
years will suffer from diabetes mellitus 2. Uncontrolled and prolonged 
hyperglycaemia in diabetic patients often leads to several macro and micro vascular 
complications. Major microvascular complications include diabetic retinopathy, 
neuropathy and nephropathy. Diabetic nephropathy is one of the most common 
complications affecting more than 30 % of diabetic patients suffering for prolonged 
periods 3. Diabetic nephropathy is leading cause of end stage renal diseases (ESRD) 
in US, Europe and Japan 4. Diabetic nephropathy is one of the leading cause of 
morbidity and mortality almost 30-40 % of ESRD patients in US are either type 1 or 
type 2 diabetic patients. A prospective study from Germany has reported that 5-year 
survival rate was less than 10 % in elderly population with type 2 diabetes, and no 
more than 40% in younger population with type 1 diabetes. In Heidelberg, 59% of 
patients admitted for renal replacement therapy in 1995 had diabetes (Figure 1).  
 
 
 
Table 1: Percentage incidence and prevalence of diabetes in German dialysis population, data 
obtained from QUASI-Niere registry (2005) 
Diabetes 
type 1 / 2 1996 1997 1998 1999 2000 2001 2002 2003 2004 
Incidence (%) 30.6 30.7 32.4 33.9 35.7 35.6 35.9 36.2 34.2 
Prevalence (%) 21.6 22.3 23.2 24.1 25.0 25.7 26.3 26.8 27.1 
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Figure 1: Incidence trends of different renal disease in the German dialysis population (data 
from QUASI-Niere registry 2007) 
 
1.1. Diabetic nephropathy and different stages 
Diabetic nephropathy is characterized by persistent albuminuria (> 300 mg/d or 
>200 mcg/min), a relentless decline in the glomerular filtration rate (GFR) and 
elevated arterial blood pressure, which is confirmed on at least 2 occasions 3-6 
months apart. Based on the GFR decline, renal physiology and albumin excretion 
progression of DN has been classified into five different stages as suggested by 
K/DOQI (Table 2) 5. 
 
Table 2: Different stages of diabetic nephropathy 
 
Designation Characteristics GFR * 
Albumin 
Excretion 
Chronology 
Prevalence in 
German 
diabetic 
population 
Stage 1 Hyperfunction 
and 
hypertrophy 
Glomerular 
Hyperfiltration 
> 90 May be 
increased 
Present at 
the time of 
diagnosis 
30-37 % 
Stage 2 Silent stage Thickened GBM 
Expanded 
mesangium 
60-90 < 200 mg/d First five 
years 
17-19 % 
Stage 3 Incipient stage Microalbuminuria 30-59 30-300 mg/d 6-15 years 19-22 % 
Stage 4 Overt diabetic 
nephropathy 
Macroalbuminuria 15-29 > 380 mg/d 15-25 years 1-2 % 
Stage 5 Uremic ESRD <15/ 
dialysis 
Decreasing 25-30 years 28 % 
*ml/min/1.73 m2, GBM; glomerular basement membrane, ESRD; end stage renal disease. 
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1.2. Pathophysiology  
1.2.1. Histomorphological changes observed in human diabetic nephropathy 
The key changes observed clinically in diabetic nephropathy are augmentation of 
extracellular matrix, thickening of the glomerular basement membrane, and 
expansion of mesangium. Where as light microscopy has shown increased solid 
spaces of the tuft, most frequently observed are as coarse branching of solid 
(Periodic Acid Schiff positive) material (diffuse glomerulopathy). Large acellular 
nodules are observed also know as Kimmelstiel-Wilson lesions/nodules (Figure 2). 
The glomeruli and kidneys are typically normal or increased in size thus, 
distinguishing DN from most other forms of chronic renal insufficiency, wherein 
renal size is reduced (except renal amyloidosis and polycystic kidney disease). 
Immune deposits are not observed. The renal vasculature typically displays evidence 
of atherosclerosis, usually due to concomitant hyperlipidemia and hypertensive 
arteriosclerosis. Electron microscopy provides a more detailed definition of the 
structures involved. In advanced disease, the mesangial regions occupy a large 
proportion of the tuft, with prominent matrix content. Further, the basement 
membrane in the capillary walls (i.e. the peripheral basement membrane) is thicker 
than normal. The severity of diabetic glomerulopathy is estimated by the thickness 
of the peripheral basement membrane and mesangium and matrix expressed as a 
fraction of appropriate spaces (e.g. volume fraction of mesangium/glomerulus, 
matrix/mesangium, or matrix/glomerulus) (Figure 2). 
Three major histological changes occur in the glomeruli of persons with diabetic 
nephropathy. First, mesangial expansion is directly induced by hyperglycaemia, 
perhaps via increased matrix production or glycosylation of matrix proteins. Second, 
thickening of GBM occurs. Third, glomerular sclerosis is caused by intraglomerular 
hypertension (induced by renal vasodilatation or from ischemic injury induced by 
hyaline narrowing of the vessels supplying the glomeruli). These different histologic 
patterns appear to have similar prognostic significance (www.emedline.com). 
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Figure 2: Renal biopsies from microalbuminuric type 2 diabetic patients (periodic acid–Schiff 
stain). (a) Normal glomerular, tubular, interstitial and vascular structures. This would be classified as 
Category I. (b) Mild mesangial expansion relative to the severity of interstitial fibrosis and tubular 
atrophy. This would be classified as Category III.J (images taken from www.emedline.com) 
 
 
1.2.2. Molecular mechanisms involved in progression and development of diabetic 
nephropathy 
 
Diabetic nephropathy is one of the major causes of morbidity and mortality in 
diabetic population. As is the case with other diabetic complications hyperglycemia 
is the underlying cause for development of DN. However, the relative significance 
of each of the proposed molecular mechanisms that have been described is yet to be 
defined (Figure 3).  
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Figure 3: Different molecular mechanisms involved in the development and progression of 
diabetic nephropathy 
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1.2.2.1. Metabolic pathways in the development of DN 
1.2.2.1.1. Hyperglycemia 
Prolonged hyperglycemia in diabetic patients is the root cause of all microvascular 
complications which develop at the later stage of the disease including diabetic 
nephropathy. Clinical studies such as Diabetes Control and Complication Trial 
(DCCT) 6 and UK Prospective Diabetes Study (UKPDS) 7 have shown that intensive 
glycemic control retards the progression and development of microalbuminuria and 
overt nephropathy. However, achieving and maintaining normal blood glucose 
levels in diabetic patients still remains a challenge. High glucose induced up 
regulation of angiotensin II (Ang II) production and several other growth factors 
such as transforming growth factor beta (TGF-β), vascular endothelial growth factor 
(VEGF) in mesangial cells and in proximal tubular cells has been confirmed in in-
vitro studies 8. In addition high glucose induces the production of superoxide by the 
mitochondrial electron transport chain 9, can activate nuclear factor kappa B (NF-
κB), in part through the stimulation of protein kinase C (PKC) activity in endothelial 
cells 9, thus contributing to the progression and development of diabetic 
nephropathy.  
 
1.2.2.1.2. Peroxisome proliferator activator receptor gamma 
Peroxisome proliferator-activator receptors (PPARs) are members of the nuclear   
hormone receptor superfamily of ligand-binding transcription factors 10, 11. 
Dysregulation of the function or activity of PPARs has been implicated in obesity, 
insulin resistance, dyslipidemia, inflammation and hypertension 12, 13. Studies in 
humans have shown that thiazolidinediones (TZDs) ameliorate microalbuminuria / 
albuminuria associated with type 2 diabetic nephropathy 14. Moreover, it has been 
shown that administration of TZDs to insulin resistant- or type 1 diabetic rats 
ameliorated albuminuria, glomerular matrix deposition, glomerulosclerosis and 
tubulointerstitial fibrosis that are hallmarks of diabetic nephropathy 15, 16. Several in 
vitro studies have also shown to ameliorate diabetes-induced mesangial and 
tubulointerstitial damage with TZDs as well 17, 18.  
The mechanism of protective effect of TZDs for diabetic nephropathy is thought to 
be due to anti-inflammatory properties independent of their insulin-sensitizing action 
Sufyan G. Sayyed 9
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indicative of role of PPAR-γ receptor in inflammation associated with diabetes. 
Recently, Tang et al. have reported interleukin-8 (IL-8) and soluble intercellular 
adhesion molecule-1 (sICAM-1) activation by stimulation with advanced glycation 
end products (AGEs) is partially ameliorated by PPAR-γ ligation in human proximal 
tubular epithelial cells 18, 19. 
 
1.2.2.1.3. Advanced glycation end products 
Under hyperglycemic conditions several proteins undergo non-enzymatic glycation 
resulting in Amadori’s products known as advanced glycation end products (AGEs). 
There are different types of AGEs that have been reported in diabetes. AGEs are 
known to be one of the major contributors in the progression of DN and other 
complications associated with diabetes. Almost all renal structures are susceptible to 
accumulate AGEs including basement membranes, mesangial and endothelial cells, 
podocytes and tubules 20. Accumulation of AGEs such as N-ε-carboxymethyllysine 
(CML) and pentosidine in the kidney leads to the progressive alteration in renal 
structure and loss of renal function that is seen in long-term diabetes in humans 18 
and rodents 21. There are several studies confirming inhibition of AGE formation 
prevents the development and progression of experimental diabetic nephropathy 18, 
22. AGEs are involved in the pathogenesis of diabetic nephropathy via multifactorial 
mechanisms 23. AGEs have been reported to induced apoptotic cell death, VEGF 
stimulation, activation of TGF-β-Smad signaling pathways and MCP-1 production 
in mesangial cells 24-26 (Figure 4).  
 
1.2.2.1.4. Polyol pathway 
The polyol pathway consists of two enzymes, aldose reductase (AR) and sorbitol 
dehydrogenase (SDH), which together convert glucose to fructose via sorbitol. 
Aldose reductase, catalyzes reduction of glucose to sorbitol, while SDH converts 
sorbitol into fructose using NAD+ cofactor 27. The polyol pathway is activated under 
hyperglycemic conditions, and is considered to play an important role in the 
development of diabetic nephropathy. Intracellular sorbitol accumulation and 
decline in nicotinamide adenine dinucleotide phosphate (NADPH) contents caused 
by increases in AR flux has been postulated to induce osmotic damage and oxidative 
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stress, respectively. Some human studies have shown that AR inhibition attenuates 
hyperfiltration in normo-albuminuria and prevents the course of microalbuminuria in 
type 1 diabetic patients 28. Although many potent AR inhibitors have been identified 
and developed (minalrestat, zenarestat, eparlestat and zopolrestat 18), none are 
currently marketed for clinical use for diabetic nephropathy. Many of the candidates 
failed to gain acceptance due to an inadequate therapeutic index and relatively high 
toxicity (Figure 4). 
 
 
Figure 4: Metabolic pathways associated with diabetic nephropathy. (Taken with little 
modifications from Imtiaz et. al 29) 6-P; 6-phosphate, DAG; diacylglycerol, PKC; protein kinase C, 
ROS; reactive oxygen species, 3DG; 3-deoxyglucosone, MG; methylglyoxal, AGE; advanced 
glycation end products.   
 
1.2.2.2. Hemodynamic pathways 
Hemodynamic changes associated with diabetes are responsible for increased 
glomerular pressure and hyperfiltration resulting in stress related glomerular 
damage, loss of podocytes, hypertrophy and glomerular changes in diabetic kidneys 
(Figure 5).  
 
1.2.2.2.1. Renin angiotensin system 
Besides its well known hemodynamic actions including direct effects on glomerular 
hemodynamics, recent studies have suggested that the intrarenal renin angiotensin 
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system (RAS) is an important regulator of renal function and structure 18, 26. 
Angiotensin II (Ang II) exerts growth stimulatory and profibrogenic effects, most 
likely via  up-regulation of growth factors such as TGF-β, platelet derived growth 
factor (PDGF), connective tissue growth factor (CTGF) and vascular endothelial 
growth factor (VEGF) and also can act as a pro-inflammatory factor 30. Recently, a 
close relationship between the RAS and AGE systems in diabetic nephropathy has 
been described. Post infusion accumulated AGEs in glomeruli and tubules were 
significantly ameliorated by valsartan treatment, an angiotensin II type 1 receptor 
(AT1R) antagonist 31. Moreover, Ang II infusion has shown to accelerate the 
accumulation of AGEs in glomeruli and tubules as well.  
These studies further strengthen the data implicating the RAS in diabetic 
complications. Hemodynamic changes resulting can cause podocyte damage leading 
to proteinuria. The role of another Ang II receptor subtype, the Ang II type 2 (AT2) 
receptor (AT2R), remains to be explored. However, this receptor subtype was 
recently shown to mediate the biological effects of Ang II; it is involved in the 
expression of RANTES and osteopontin as well as modulation of NO release and 
prostaglandin E2 (PGE2) production 18. 
 
1.2.2.2.2. Endothelin pathway 
Vascular complications associated with diabetes contribute to the development of 
diabetic nephropathy. Diabetic nephropathy is associated with enhanced renal 
synthesis of endothelin (ET), one of the most potent endogenous vasoconstrictors 32. 
There are two receptor subtypes for ET, namely A and B. ET typeA receptors are 
found predominantly in vascular smooth muscle cells, mediating vasoconstriction 
and cell proliferation 33. In contrast, ET typeB receptors are usually found on 
endothelial cells, and mediate vasodilatation via NO 34. Therefore, there may be 
potential benefits of specifically blocking the ET typeA receptor while preserving 
the vasodilator function of the ET typeB receptor. Darusentan is a new, non-peptide, 
selective ET receptor antagonist that acts predominantly on ET typeA receptors 35. 
Experimentally in STZ-treated rats, a longterm treatment with darusentan 
completely abolished overexpression of glomerular fibronectin and type IV 
collagen, and reduced protein excretion by about 50% as compared to untreated 
Sufyan G. Sayyed 12
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diabetic rats 36 indicates potential role ET typeA receptor antagonists in the 
treatment of diabetic nephropathy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Hemodynamic and pro-inflammatory pathways associated with diabetic 
nephropathy.  (Taken with little modifications from Imtiaz et. al 29) PKC; protein kinase C, AGE; 
advanced glycation end products, TNF-α; tumor necrosis factor alpha, VEGF; vascular endothelial 
growth factor, CTGT; connective tissue growth factor, ECM; extra cellular matrix.  
 
1.2.2.3. Involvement of growth factors 
1.2.2.3.1. Transforming growth factor (TGF-β) Elevated levels of TGF-β have 
been well documented in the diabetic kidney. It is well known to accelerates the 
development and progression of diabetic renal injury 37. Several in vivo- and in vitro 
studies have implicated TGF-β as a key mediator in advanced diabetic renal disease, 
which mediates Ang II induced prosclerotic action, at least in part 37, 38. Ziyadeh et 
al. have shown the effects of long-term administration of a neutralizing TGF-β 
antibody on the renal function and renal histology of db/db mice, an experimental 
model of type 2 diabetes 37. Treatment with neutralizing TGF-β antibody completely 
prevented the increases in plasma creatinine, collagen and fibronectin expression, 
and the mesangial matrix expression in db/db mice. Therefore, inhibition of TGF-β 
expression may be useful in diabetic nephropathy. Use of TGF-β antibodies in 
humans remains uncertain since TGF-β and its expression is yet not fully 
characterized.  
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1.2.2.3.2. Connective tissue growth factor (CTGF) Increased CTGF expression has 
been confirmed in the plasma of type 1 diabetic patients with nephropathy, and also 
in glomeruli from diabetic rodents 39. CTGF act as a downstream factor of TGF-β in 
the development of diabetic nephropathy 18, 40. Experimental evidences have 
suggested an active role of CTGF in early- and late-stage morphologic changes in 
diabetic nephropathy including the damage resulting from hyperglycemia and 
hypertension, leading to proteinuria and fibrosis. Recent study with FG-3019 has 
shown normalized kidney filtration and weight in db/db mice upon treatment with a 
recombinant monoclonal antibody designed to bind and neutralize CTGF 41.  
 
1.2.2.3.3. Platelet derived growth factor (PDGF) PDGF is a polypeptide that was 
originally purified from human platelets as a potent mitogen for fibrosis, osteoblasts, 
smooth muscle and mesangial cells 42. PDGF has been suggested to play a role in the 
pathophysiology of various fibroproliferative diseases of the kidney 43, 44.  
Upregulation of the PDGF pathway has been shown in experimental diabetic 
nephropathy and in the kidneys from patients with diabetes 45. Furthermore, 
amelioration of diabetic nephropathy by an inhibitor of advanced glycation, 
aminoguanidine, was associated with reduced renal PDGF expression 46. The 
inhibition of PDGF, in vitro, resulted in a significant reduction in mesangial cell 
proliferation, and largely prevented the increased deposition of ECM associated with 
the disease 47. Increased mesangial cell proliferation is well documented in DN and 
inhibition of PDGF may retard mesangial cell proliferation and ECM deposition and 
might improve the disease progression 48.  
 
1.2.2.3.4. Vascular endothelial growth factor (VEGF) VEGF is a cytokine which 
plays a major role in development of diabetic nephropathy and has been extensively 
studied. VEGF is found to be upregulated early in type 1 diabetic rodents, especially 
in podocytes 49. Blockade of VEGF by neutralizing antibodies in type 1 diabetic rats 
abolished hyperfiltration and suppressed the urinary albumin excretion (UAE) rate 
50. In addition, VEGF contributes to renal matrix accumulation, since treatment with 
anti-VEGF antibodies has attenuated GBM thickening and mesangial expansion in 
db/db mice 51. Recently, one study has demonstrated that a neutralizing VEGF 
antibody prevents glomerular hypertrophy in Zucker diabetic fatty rat (a model of 
obese type 2 diabetes) 52. VEGF regulates transcription of chemokies like CXCL12 
Sufyan G. Sayyed 14
Chemokines and Diabetic Nephropathy 
which may contribute to the disease progression. VEGF upregulation has been 
correlated with DN and inhibition of VEGF may retard mesangial cell proliferation 
and matrix accumulation. 
 
1.2.2.4. Inflammation and diabetic nephropathy 
 
Over the past decade, a number of important research developments in the area of 
diabetic nephropathy have contributed to understanding of the disease. Beyond the 
hemodynamic and metabolic abnormalities, inflammatory processes and immune 
cells are involved in development and progression of diabetic nephropathy 53. There 
are increasing evidences, which suggests that immune cells participate in the 
vascular injury in the conditions of DN, and their migration into the kidney is a 
crucial step in the progression of this disease 54. Increased glomerular and interstitial 
infiltration of macrophages/monocytes has been confirmed in diabetic rodents as 
well as human renal biopsies, and recent studies demonstrate that macrophage-
derived products can induce further inflammation in the diabetic kidney 55-57. 
Furthermore, activated T lymphocytes have been associated with DN 58. One of the 
most striking features of leukocytes from patients with diabetes is the activated 
status of blood neutrophils 59, 60.  
 
Little is known about the migration patterns of different types of immune cells into 
renal tissues in DN. Homing of neutrophils is thought to be a hallmark of acute 
kidney inflammation, and recruitment of macrophages and T cells indicates chronic 
inflammatory processes 57, 61. Although the detailed mechanisms of leukocyte 
migration to renal tissues are not completely understood, there is evidence that 
selectins, integrins and chemokines participate in this recruitment 54. Upregulation of 
ICAM-1 expression has been confirmed in human renal biopsies as well as in 
rodents which facilitates neutrophils/macrophage infiltration into kidney. 
Hyperglycemia induced PKC activation further contributes to chemokine expression 
in renal cells and in immune cell infiltrates. Therapeutic intervention targeting 
protein kinase C can disrupt this positive amplification loop by reducing renal 
chemokine expression, subsequent recruitment of immune cells, and tubular injury 
in experimental and human diabetic nephropathy 62, 63. The relevance of these 
experimental data for human disease was supported by transcriptome analysis of 
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human renal biopsy samples from patients with diabetic nephropathy that identified 
a specific NF-κB promoter-dependent inflammatory stress response in progressive 
diabetic nephropathy 64. The contribution of inflammation to the progression of 
diabetic nephropathy has become increasingly anticipated. 
 
1.2.2.4.1. T Lymphocyte recruitment to kidney  
Although trafficking of naive, effector, and memory T cells into peripheral lymph 
nodes, spleen, skin, gut, and liver has been the subject of extensive studies the 
mechanisms of T cell homing into the kidney under different pathologic conditions 
are not fully identified. The fundamental appreciation of the importance of the 
leukocyte recruitment in the induction of endothelial dysfunction has significantly 
changed the view of the pathogenesis of DN. Because naive as well as effector T 
cells constitutively express LFA-1, and ICAM-1 expression is found on renal 
endothelial, epithelial, and mesangial cells 65, 66, it is likely that this interaction will 
play a significant role during T cell migration into kidney. Indeed, homing of CD4+ 
T cells into glomeruli of diabetic kidney was decreased in ICAM-1 deficient-db/db 
mice compared with normal db/db mice 67. It should be noted that the activation of 
CD4+ and CD8+ T cells by AGEs can initiate IFN-γ secretion by T cells 68, which 
can induce further inflammation and oxidative stress within renal tissues. T cell 
accumulation is also found in the juxtaglomerular apparatus of patients with type 1 
diabetes 58. The functional role of T cells within this compartment is not clear yet, 
but this T cell influx is common among young patients with type 1 diabetes, 
especially those with accelerated duration of diabetes, and correlates with 
glomerular filtration surface and albumin excretion rate 58. A T helper-1 (Th1) 
response precedes and accompanies type 1 diabetes 69; therefore, it is possible that 
accumulation of Th1 cells will be prevalent in diabetic kidney. Little is known about 
the homing of Th1 cells during the development and progression of kidney diseases. 
It has been reported that the homing of effector Th1 cells in glomeruli is P-selectin 
and ICAM-1 dependent and associated with increased levels of IFN-γ and MIF in 
crescentic Th-1–mediated glomerulonephritis 70. Although the mechanisms of Th1 
cell migration in models of DN have not been reported yet, elevated levels of 
ICAM-1 and P-selectin within the diabetic kidney were found. Further studies will 
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elucidate the possible role of these adhesion molecules in the migration into the 
diabetic kidney 54.  
1.2.2.4.2. Neutrophil recruitment  
Neutrophil influx is associated with the acute response to inflammation or injury. 
Neutrophils secrete enzymes and products of oxidation that can harm the local 
microenvironment and induce tissue damage. The role of neutrophils in the 
development of DN is not well understood; however, there is some evidence that 
neutrophils might be involved in this pathologic process. Abnormal activation of 
blood neutrophils has been reported in patients with type 1 and type 2 diabetes 59, 60 
suggesting possible involvement of neutrophils in diabetic nephropathy. Takahashi 
et al. 60 showed that spontaneous adhesion of neutrophils from patients with diabetes 
is increased significantly compared with adhesion of neutrophils from patients with 
normoalbuminuria as well as healthy control subjects and was associated with 
increased ICAM-1 expression. The precise molecular mechanisms that orchestrate 
trafficking of neutrophils in diabetic kidney are not yet defined, but studies with 
other models of kidney pathology suggest that selectins and integrins might 
participate in this process. Expressions of both E- and P-selectin was increased in 
the glomeruli and interstitial capillaries of human diabetic kidneys compared with 
kidneys of other glomerular diseases 71.  
 
1.2.2.4.3. Macrophage recruitment 
Infiltrating glomerular and interstitial macrophages are hall mark of renal vascular 
inflammation, and their accumulation is a characteristic feature of DN 55, 56. 
Infiltrated M/M (Monocytes/Macrophages) release various substances including 
lysosomal enzymes, nitric oxide, reactive oxygen intermediates or TGF-beta which 
are essential mediators of renal damage 72.Adoptive transfer studies show that 
macrophages can induce proteinuria and mesangial proliferation in a model of 
experimental glomerulonephritis 73. Therefore, it is possible that infiltrating 
macrophages might induce or accelerate the mesangial cell proliferation during the 
development of DN.  
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Detailed molecular mechanisms that direct macrophage migration are not fully 
characterized, but chemokines/chemokine receptors as well as integrins are involved 
in this process. Increased expression of ICAM-1 that serves as a ligand for LFA-1 
was detected in models of type 1 65 and type 2 DN 66, 74. ICAM-1 expression can also 
be induced by factors such as hyperglycemia 75, AGE 76, oxidative stress 77, and 
hyperinsulinemia 78. Diminished infiltration of macrophages, reduced expression of 
TGF-β and collagen IV in glomeruli, reduced urinary albumin excretion, glomerular 
hypertrophy, and mesangial matrix expansion are associated with reduced renal 
injury in diabetic ICAM-1 deficient mice 79. In a model of type 2 diabetes, Chow et 
al. 67 used ICAM-1 deficient db/db mice and showed significant reduction in 
albuminuria and a decrease in the number of glomerular and interstitial macrophages 
that was associated with reduced glomerular hypertrophy, hypercellularity, and 
tubular damage. Both studies indicate, a role of ICAM-1 in macrophage infiltration 
into renal compartment 67.  
 
1.2.2.5. Chemokines and chemokine receptors in diabetic nephropathy 
Chemokines are a large family of small secreted proteins of 8–14 kDa that control 
cell trafficking. They are structurally divided into four classes —C, CC, CXC, and 
CX3C—depending on the number and the relative position of their amino terminal 
cysteine residues 80. Individual chemokines are named using the acronyms of the 
structural class they belong to, followed by an L (for ligand) and their gene number 
81, 82. 
 
Chemokine receptors are themselves classified according to the chemokine family 
they bind. The nomenclature of the receptors is analogous to that of chemokines, 
using the family acronym followed by an R (for receptor) and a number that 
corresponds to the order of its discovery 83 Chemokine receptors belong to class A 
of the G protein–coupled receptor (GPCR) superfamily. They are rhodopsin-like 
receptors with 7 transmembrane structure coupled with heterotrimeric Gαβγ proteins 
84. Upon ligand–receptor interaction, different intracellular signaling pathways are 
activated, ultimately leading to cell mobilization and activation 82, 85 (Figure 6). 
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From a functional point of view, chemokines can be divided into inflammatory, 
homeostatic, and dual function chemokines 86. Inflammatory chemokines are 
induced by pathogens, cytokines, or growth factors and recruit effector leukocytes to 
sites of infection, inflammation, tissue injury, and tumor. CCR1, CCR2, CCR3, 
CCR5, CXCR2, XCR1, and CX3CR1 are some examples of receptors that bind 
inflammatory chemokines. Homeostatic chemokines are expressed in bone marrow 
and lymphoid tissues and are involved in homing and migration, hematopoiesis, 
immune surveillance, and adaptive immune responses. The receptors for 
homeostatic chemokines (CCR7, CXCR4, and CXCR5) are expressed on B cells, 
follicular-helper T cells, central-memory T cells, and mature dendritic cells, among 
others. Chemokines that share properties of these two groups are classified as dual 
function. These chemokines are involved in adaptive immunity, T lymphopoiesis, 
dendritic cell development, and homing to particular anatomic compartments. 
Regulatory T cells, CLA4+ cells (homing to skin), and α4β7+ cells (homing to 
intestinal mucosa) express receptors for these chemokines (CCR4, CCR6, CCR8, 
CCR9, CXCR3, and/or CXCR6).  
 
 
Figure 6: Chemokines and chemokine receptors.  (Taken from Proudfoot et. al. 87) 
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1.2.2.5.1. Pro-inflammatory chemokines and receptors 
1.2.2.5.1.1. Monocyte chemoattractant protein-1 (MCP-1/CCL2) 
CCL2 also known as MCP-1 is a member of CC class of chemokine which binds to 
CCR2, a chemokine receptor CCL2 is believed to play a key role in recruitment of 
M/M into different renal compartments. It is secreted by mononuclear and various 
non-leukocytic cells including renal resident cells 88, 89. Its role in experimental 
glomerulonephritis models 90 and human nephritis 91, crescent formation and 
progressive tubulointerstitial lesions via M/M recruitment and activation has been 
reported. In patients with diabetic nephropathy urinary CCL2 levels were 
significantly elevated at different stages of DN, and were correlated with the number 
of CD68-positive infiltrating M/M in the interstitium 92, 93. Immunohistochemical 
and in situ hybridization analyses revealed CCL2 positive cells localize within 
tubulointerstitial lesions 92. Furthermore, in Japanese patients with type 2 diabetes 
increased urinary CCL2 excretion was positively correlated with the tubular damage 
marker N-acetylglucosaminidase and albuminuria, indicating that increased tubular 
CCL2 expression contributes to renal damage 94. Recently CCL2 deficient mice with 
streptozotocin-induced diabetes demonstrated attenuated diabetic nephropathy, with 
marked reductions in glomerular and interstitial macrophage accumulation, 
histological damage, and renal fibrosis when compared with the wild-type 95. In 
db/db mice, CCL2 deficiency reduced renal M/M accumulation and the progression 
of diabetic renal injury independent of development of obesity, insulin resistance or 
type2 diabetes 96. High glucose mediated enhanced expression of CCL2 in human 
mesangial cells via NF-κB activation has been confirmed in many in-vitro studies 97. 
In addition renal biopsies of patients with type 2 diabetes and overt nephropathy, 
showed a strong up-regulation of CCL2 mainly in the tubular cells which was 
positively correlated with NF-κB activation in the same cells 98, 99. In cultured 
human mesangial cells, AGE mediated enhanced apoptotic cell death was associated 
with concomitant increased expression of CCL2 24. In another study mechanical 
stretching of human mesangial cells resulted in over expression of CCL2 via NF-κB 
100 which was accelerated in presence of high glucose medium 100. Some in vitro and 
in vivo data provides evidence that angiotensin II (Ang II) directly induces the 
expression of CCL2. This can be further supported by study showing treatment with 
the ACE inhibitor, enalapril and the AT1-receptor antagonist, candesartan 
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dramatically suppressed renal CCL2 expression in streptozotocin treated rats 101 and 
was associated with a marked reduction in renal M/M infiltration and proteinuria. A 
similar study has reported reduction in glomerular and tubular CCL2 expression and 
amelioration of renal damage with reduced M/M infiltration in Zucker rats upon 
treatment with olmersartan 102. Treatment with ACE inhibitors or AT1-receptor 
blockers led to a reduction of urinary CCL2 excretion, improvement of renal 
function, and reduction of oxidative stress in patients with type 1 and 2 diabetes 103, 
104. Addition of CCL2 to cultured macrophages resulted in enhanced secretion of 
TGF β1, which in turn increased expression of collagen type I and III as well as 
fibronectin in renal interstitial myofibroblasts 105. Furthermore, CCL2 also mediates 
collagen deposition in experimental glomerulonephritis by TGF-β 106 independent of 
M/M infiltration 53, 107. In addition one of the studies from our lab has demonstrated 
the effect of late onset of CCL2 blockade in uninephretomized type 2 db/db mouse 
model 61. CCL2 blockade using mNOX-E36–3_PEG reduced the number of 
glomerular macrophages by 40% in 1K db/db mice which was associated with 
protection from diffuse glomerulosclerosis and significantly improved the 
glomerular filtration rate 61. Another study has reported administration of anti–CCL2 
antibodies prevents glomerular sclerosis and interstitial fibrosis 90.  
 
Most of the pathological changes associated with diabetes including hyperglycemia, 
AGEs, hemodynamic changes and oxidative stress results in over expression of 
CCL2 in renal cells. CCL2 over expression plays a central role in disease 
progression and renal inflammation through M/M recruitment to different renal 
compartments. CCL2 activation serves as common pathway towards development 
and progression of DN. Thus targeting CCL2 in diabetic nephropathy may turn more 
beneficial than targeting each pathway.   
 
1.2.2.5.1.2. Fractalkine (CX3CL1) 
Fractalkine/CX3CL1 exists in membrane- bound as well as in soluble form, and 
therefore acts as a chemoattractant and adhesion molecule 108. In diabetes mellitus, 
fractalkine/CX3CL1 expression is upregulated in human kidneys along the 
glomerular and peritubular capillaries 109. The corresponding receptor for 
fractalkine, CX3CR1, is expressed mainly on monocytes 110, 111. In the diabetic rat 
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kidney mRNA expression of fractalkine/CX3CL1 and CX3CR1 was found to be 
increased and some CX3CR1 positive cells are M/M 109. Up-regulation of 
fractalkine/CX3CL1 was induced in proximal tubular cells by protein overload 
through NF-κB and p38 mitogen activated protein kinase-dependent pathways 112. 
Moreover, AGEs 113 and TNF-alpha 114 also induce fractalkine/CX3CL1 in the 
kidney. In an in vitro study fractalkine/CX3CL1 mediated arrest and migration of 
CD16+ monocytes, suggesting that fractalkine might function as an arrest 
chemokine in the pathway of M/M adhesion before migration into the diabetic 
kidney 115. However, the extent to which fractalkine/CX3CL1 is involved in the 
recruitment of T lymphocytes remains controversial. Fractalkine/CX3CL1, 
RANTES/CCL5 and gamma-interferon-inducible-protein (IP-10/CXCL10) have 
been identified as responsible chemokines for mediating attraction of T cells 53. The 
role of fractalkine in progression and development of diabetic nephropathy is yet to 
be explored.  
 
1.2.2.5.1.3. RANTES / CCL5 
Another important CC-chemokine in diabetic nephropathy, RANTES/CCL5, is a 
potent chemoattractant for M/M and granulocytes, but also for T cells, and is 
involved in enhanced chronic inflammation. CCL5 is expressed by various cell types 
including lymphocytes, fibroblasts, mesangial cells and renal tubular epithelial cells 
116, 117. Molecular studies have identified NF-κB binding sites within the promoter 
region of the CCL5 gene 118. In kidney, up-regulation of CCL5 predominantly in 
mesangial and tubular is induced by effectors such as, NFκB dependent pathways 64, 
protein overload 119, activation of the RAS 120, enhanced glomerular filtration of 
growth factors such as TGF-β 121, and cytokines such as TNF-α 122. The exact role of 
CCL5 in directing the T lymphocyte recruitment into the diabetic kidney is not 
completely known. T cell clusters have been found in the juxtaglomerular apparatus 
in renal biopsies from patients with type 1 diabetes 58. Interestingly, T cell positive 
patients had a shorter duration of diabetes than T-cell negative patients and a lower 
albumin excretion rate, but the glomerular filtration rate was not different. These 
findings suggest that possibly T cells play a preservative role for renal function 53, 58. 
Treatment with AOP-RANTES a receptor blocker has shown inhibition of 
infiltrating macrophages in a rat model 123.  
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1.2.2.5.1.4. Interferon-gamma inducible protein (IP-10 / CXCL10) 
Microvascular damage is a characteristic of diabetic nephropathy. A selective 
upregulation of IP-10/CXCL10 by endothelial cells in the tubulointerstitial area, co-
localizing with infiltrating T cells, was found in a model of renal endothelial 
microvascular injury in rats. Despite extensive damage of glomerular vasculature, no 
IP-10/CXCL10 expression by glomerular endothelial cells was detected. In contrast, 
MCP-1/CCL2 mRNA was upregulated in the glomerulus and the tubulointerstitium 
124. Treatment with a neutralizing anti–IP-10/CXCL10 antibody significantly 
reduced the number of infiltrating tubulointerstitial T cells without affecting M/M 
migration and led to improved renal function 124. This study demonstrates a role for 
IP-10/CXCL10 on T cell recruitment in renal endothelial microvascular injury in 
rats. However, there are no reports describing role of CXCL10 in development and 
progression of diabetic nephropathy 53.  
1.2.2.5.1.5. CX3CR1  
Chemokine C-X3-C motif receptor 1 (CX3CR1), the receptor for fractalkine, was 
found on infiltrating M/M, and on T cells in different renal compartments. In a 
model of streptozotocin treated rats, CX3CR1 was found to be upregulated in 
diabetic nephropathy 109. In glomerular disease with prominent M/M infiltration, the 
distribution of M/M matched the distribution of CX3CR1 and in interstitial 
infiltrates the distribution of CX3CR1 corresponded to the distribution of both T 
cells and M/M 125. The pattern of CX3CR1 expressing cells was consistent with its 
ligand fractalkine. The co-localization of CX3CR1 and fractalkine argues for the 
hypothesis that the CX3CR1/fractalkine complex mediates adhesion in the early 
extravasation cascade, whereas the ligands of CCR2 and CCR5 might guide 
inflammatory cells to more specific renal compartments 125.  
 
1.2.2.5.1.6. CCR1  
Chemokine C-C motif receptor 1 (CCR1) has been identified recently as playing a 
critical role in the recruitment of renal interstitial M/M 57. In one of the studies from 
our lab we used a CCR1 antagonist to block interstitial M/M recruitment in 
uninephrectomized db/db mice, an accelerated model for advanced nephropathy of 
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type 2 diabetes 57. CCR1 blockade reduced interstitial M/M infiltration, most likely 
by interfering with M/M adhesion to activated endothelial cells of peritubular 
capillaries in the renal interstitium 57. Furthermore, a reduction of proliferating 
tubular epithelial and interstitial cells, tubular atrophy, and interstitial fibrosis was 
observed 57 thus, indicating role of CCR1 in macrophage infiltration to interstitium. 
Glomerular macrophage infiltration was not affected with CCR1 blockade in mice. 
 
1.2.2.5.1.7. CCR2  
Chemokine C-C motif receptor 2 (CCR2) is CC chemokine receptor mainly 
expressed on monocytes, basophils, memory T cells and pDCs. CCR2, acts as 
receptor for CCL2 (MCP-1), CCL13 (MCP 4), CCL7 (MCP3) and CCL8 (MCP2), 
is mainly represented by the distribution of M/M in renal tissue 126. Inhibition of 
CCR2 by receptor antagonists as well as a CCR2 knockout mice model are 
characterized by a reduced degree of M/M infiltration and abolished renal fibrosis 
127. CCR2 blockade prevents renal fibrosis in UUO kidney 127. Monocyte and 
macrophage trafficking is mediated through CCR2 in ischemia-reperfusion injury 128 
as well as in monocytogenic infection 129. Similar effects could be shown by the 
delivery of a mutant of the MCP-1/CCL2 gene into mice 130. In CCR2 deficient mice 
tubular necrosis and the number of infiltrating M/M were significantly lowered after 
transient renal ischemia 131. Targeted macrophage depletion has been shown to 
ameliorate mesangioproliferative glomerulonephritis in rats 132 which was associated 
with reduction of infiltrating macrophage in glomerular compartment, alpha smooth 
muscle actin and fibronectic 132. Recruitment of monocytes and macrophages to 
renal compartments is considered to be hallmark of DN development and 
progression. Thus targeting CCR2 blockade using some specific antagonist remains 
attractive for treating DN and yet to be explored. 
 
1.2.2.5.1.8. CCR5  
Chemokine C-C motif receptor 5 (CCR5) is a CC chemokine receptor which is 
mainly expressed on monocytes, T cells, NK cells, pDCs and immature DC. CCR5 
acts as common receptor for many chemokines including CCL8 (MCP2), CCL4 
(MIP 1β), CCL3 (MIP 1αS), CCL3L1 (MIP 1αP) and CCL5 (RANTES). 
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Chemokine receptor CCR5 gene polymorphism has been reported in Indian patients 
with ESRD 133 as well as in Japanese diabetic  nephropathy patients 134. Another 
study has reported overexpression of CCR5 on peripheral blood mononuclear cells 
in patients with type 2 diabetes 135. A human renal biopsy study of patients with 
various renal diseases showed that glomerular CCR5-positive cells were closely 
correlated with extracapillary lesions and urinary MIP-1α/CCL3 levels, while 
interstitial CCR5-positive cells, mainly CD3-positive T cells, were correlated with 
interstitial lesions and urinary CCL5 levels 92. NF-κB mediated MIP 1α-CCR5 
signaling upregulation has been implicated in development of human crescentic 
glomerulonephritis 136 and in islet allograft rejection 137. Role of CCR5 gene 
polymorphism in renal allograft survival is also documented 138. CCR5 receptor 
antagonist AOP-RANTES has been reported to reduce number of infiltrating 
macrophages in glomerular compartment as well as reduced collagen IV deposition 
in a rat model of glomerulonephritis 123. Many studies have confirmed the role of 
infiltrating macrophages and immune cells in the development and progression of 
diabetic nephropathy. Targeting CCR5 receptor in order to achieve amelioration of 
disease by inhibiting infiltration of monocytes and T cells is quite attractive, but a 
recent study by Turner et al has reported CCR5 deficiency aggravates 
glomerulonephritis in mice which was associated with counter upregulation of 
CCL3, CCL5 and CCR1139. Another study has reported renal as well as cardiac 
allograft rejections in CCR5 deficient mice 140. Both studies are indicative of CCR5 
blockade results in counter upregulation of other chemokines and chemokine 
receptors. Inhibition of CCR5 in diabetic nephropathy remains to be explored yet. 
  
1.2.2.5.2. Homeostatic chemokines and their receptors 
 
Homeostatic chemokines are expressed in bone marrow and lymphoid tissues and 
are involved in hematopoiesis, immune surveillance and adaptive immune responses 
86. The receptors for homeostatic chemokines (CXCR4, CXCR5 and CXCR7) are 
expressed on B cells, follicular-helper T cells, central-memory T cells, and mature 
dendritic cells. Some chemokine receptors bind specifically to only one ligand (e.g. 
CXCR4 and CXCL12, CXCR5 and BLA-1) while others share the binding domain 
with more than one chemokines (e.g. CCR7 binds to MIP-3 β, SLC).  
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1.2.2.5.2.1. CXCL12 / SDF-1α 
Chemokine C-X-C motif ligand 12 (CXCL12) also know as stromal cell-derived 
factor-1 alpha (SDF-1α), was first identified as a lymphocyte homing chemokine 141. 
Until recently CXCR4 was reported to be the only receptor for CXCL12, recently 
CXCR7 has been confirmed as another receptor for CXCL12. Different effects of  
CXCL12 are mediated via its biding to CXCR4 and CXCR7 142. CXCL12 is an 
extensively studied chemokine and has been reported to mediate beneficial as well 
as pathological responses in various conditions. CXCL12 and CXCR4 expression 
levels are highly modified under pathophysiological condition in different cells like 
hypoxia induced enhanced expression in microglia 143, enhanced expression in 
cerebral ischemia in rat brain 144 and increased CXCR4 expression in distal as well 
as proximal tubules in human renal biopsies from diabetic patients 145. 
In fact, some biological effects of CXCL12 support tissue reoxigenation and 
regeneration. For example, CXCL12 has shown to induce angiogenesis 146, and  
promote cell survival 147. CXCL12 supports vascular integrity similar to VEGF 148 
and recruits bone marrow-derived progenitor cells 149-151, In this regard CXCL12 
was shown to be a crucial mediator of repair in a number of different disease models 
like pancreatic beta cell loss in type 1 diabetes 147, endovascular injury 150, vascular 
occlusion 149, 152, ischemic acute renal failure 151, stroke and myocardial infarction. 
Recently it has been reported that CXCL12-CXCR4 axis plays a key role in 
development of renal vasculature during embryogenesis 153. This study by 
Takabatake et al. reported that CXCL12 secreting stromal cells surround CXCR4 
positive epithelial components of early nephrons and blood vessels in embryonic 
kidney. In glomeruli CXCL12 secreting podocytes were found in close proximity to 
CXCR4 positive endothelial cells. Both CXCL12 and CXCR4 deficiency resulted in 
impaired vascular development 153.  
In contrast to the beneficial effects mediated by CXCL12 in tissue repair and 
regeneration, administration of CXCL12 antagonist to NZB mice has prevented the 
production of auto-antibodies  154 indicating its potential in ameliorating lupus 
nephritis. Recently another study has reported beneficial effect of a peptide 
antagonist of CXCR4 in lupus nephritis 155. A study has reported enhanced 
production of IL-6 by CXCL12 in microglia 156. However, in chronic disease states 
injury response mechanisms are often maladaptive and rather promote disease 
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progression to organ failure. For example, CXCL12 was found to potentiate NF-κB 
ligand-induced osteoclast differentiation and initiate pro-inflammatroy responses 
implicating its involvement in rheumatoid arthritis 157. CXCL12-mediated fibrocyte 
recruitment aggravates bleomycin-induced pulmonary fibrosis 152, 158-160 or 
CXCL12-driven neoangiogenesis drives diabetic eye disease 146, hemangioblastoma 
and renal cancer 161. Furthermore, CXCL12 attracts circulating tumor cells as a 
tissue-based mechanism for cancer metastasis 162. CXCL12 can also promote VEGF 
mediated tumor angiogenesis 163. In addition CXCL12 has been implicated to play 
important role in chronic allograft rejection in rats 164. These studies suggest that 
CXCL12 creates microenvironments that maintain niches for the homing of other 
cells including progenitor cell recruitment during repair. However, this function may 
also drive tissue- and disease-specific maladaptive disease pathomechanisms. 
The role of CXCL12 in glomerular disease is still to be explored. Nephrotoxic serum 
nephritis specifically induces glomerular CXCL12 expression 11. In addition, 
transgenic over-expression of CXCR4 (by knocking out Von-Hippel-Lindau gene) 
induced podocyte proliferation and glomerular crescent formation in mice 11. In 
lupus-like immune complex glomerulonephritis of NZB/NZW mice glomerular 
CXCL12 expression mainly originated from podocytes 154. Blocking CXCL12 
prevented glomerulonephritis which was attributed to less autoantibody production 
and T cell recruitment to glomeruli 154. So far nothing is known about CXCL12 in 
diabetic nephropathy. Diabetic nephropathy is devoid of either podocyte 
proliferation or autoimmunity, hence, the aforementioned studies hardly predict the 
predominant functional role of CXCL12 in diabetic nephropathy. We speculated that 
progressive remodelling of the glomerular structure to glomerulosclerosis, a 
morphological variant of wound healing, might involve CXCL12 signalling. Based 
on the available data from other disease states it is unclear whether CXCL12 
predominantly protects from diabetic nephropathy (e.g. by maintaining tissue 
integrity and supporting regeneration) or it contributes to progression of diabetic 
nephropathy (e.g. by enhancing glomerulosclerosis).  
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1.2.2.5.2.2. CXCR4  
Chemokine C-X-C motif receptor 4 (CXCR4) also known as Fusin, is one of the 
receptors for CXCL12. CXCR4-CXCL12 axis has been reported to initiate G-
protein signaling and is responsible for several physiological and pathological 
responses. The expression of CXCR4 (and CXCL12) is controlled by hypoxia-
regulated factor (Hif)-α, a transcription factor that orchestrates intrarenal expression 
in tissues when being exposed to hypoxia or oxidative stress 165. CXCR4 expression 
was enhanced in microglia under hypoxic condition 143. Another study has reported 
VEGF induced increased expression of CXCR4 in human endothelial cell 166.  
1.2.2.5.2.3. CXCR7 
Chemokine C-X-C motif receptor 7 (CXCR7) also known as RDC1, is highly 
conserved between mammalian species as revealed from the sequences from human, 
dog, mouse and rat 167. CXCR7 has shown high affinity for CXCL12 and ITAC. A 
characteristic of chemokine receptor is their signaling via petussis toxin sensitive Gi-
proteins 168, but coupling of CXCR7 to G-proteins has not been demonstrated yet. 
Most of the chemokine recptors contain a conserved DRYLAIV motif at N-terminus 
of the second intracellular loop which is assumed to be necessary but not sufficient 
for coupling to Gi-proteins. The sequence of CXCR7 is altered at two positions (A/S 
and V/T). Survival and efficient differentiation of B cells into antibody producing 
cells correlates with CXCR7 levels at the plasma membrane 169 at the same time 
proliferative activity of CXCR7 was also reported in fibroblasts 170 recently 
CXCL12 binding to CXCR7 has been shown to be responsible for renal progenitor 
cell adhesion to endothelial cells and for renal progenitor cell survival 171. In a very 
interesting study recently Angelique, et al have shown CXCR7 heterodimerization 
with CXCR4 in CXCL12 mediated G-protein signaling 172.  Further studies in this 
field will be helpful in our understanding of CXCR7 as receptor for CXCL12. 
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2. Summary and hypothesis   
2.1. Role of pro-inflammatory chemokines in diabetic nephropathy 
Beyond hemodynamic and metabolic abnormalities associated with diabetes, the 
role of inflammation in development and progression of diabetic nephropathy is well 
accepted. Recruitment and activation of macrophages in different renal compartment 
is considered to be hallmark of all inflammation in diabetic nephropathy. Although 
recruitment of macrophages to the renal compartment has been extensively studied, 
the exact mechanisms involved are still to be explored. The chemokine-chemokine 
receptor interactions are implicated to be mainly responsible for trafficking and 
infiltration of different monocytes and macrophages. Contribution of macrophages 
to the development of DN can be addressed in either by inhibiting chemokines or 
chemokine receptor associated with diabetes.  
 
We hypothesized that inhibition of CCL2 may inhibit macrophages infiltrating into 
different compartments in kidney and inhibition started at earlier stage of disease 
progression may show more beneficial effects than CCL2 blockade at late stage of 
DN. To address the involvement of additional chemokine receptors we hypothesized 
that blocking CCR5 and CCR2 simultaneously might have some additive or 
synergistic effects. 
 
2.2. Role of homeostatic chemokines in diabetic nephropathy 
Homeostatic chemokies are mainly involved in hematopoeisis, immune cell survival 
and adaptive immune responses. CXCL12 attracted our attention as it is being 
extensively studied and reported to be responsible for different functions like stem 
cell survival and homing and trafficking to different compartments. The role of 
CXCL12 in diabetic nephropathy has not been explored yet. CXCL12 is 
constitutively expressed by different renal cells. It may contribute to tissue repair 
and inhibit disease progression by stem cell recruitment or may cause increased 
tissue fibrosis and aggravate the disease. 
We hypothesized that CXCL12 plays role in development and progression of 
diabetic nephropathy. In order to address this question we used CXCL12 blocker in 
a mouse model of diabetic nephropathy.  
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3. Materials and methods 
3.1. Equipments and instruments  
Balances:       
Analytic Balance,  
BP 110 S    Sartorius, Göttingen, Germany 
Mettler PJ 3000                                  Mettler-Toledo,Greifensee, Switzerland 
 
Cell Incubators: 
Type B5060 EC-CO2   Heraeus Sepatech, München, Germany 
Centrifuges: 
Heraeus, Minifuge T   VWR Internationl, Darmstadt, 
Germany 
Heraeus, Biofuge primo                       Kendro Laboratory Products GmbH,    
Hanau, Germany 
Heraeus, Sepatech Biofuge A  Heraeus Sepatech, München, Germany 
ELISA-Reader 
Tecan, GENios Plus   Tecan, Crailsheim, Germany 
Fluorescence Microsocopes 
Leica DC 300F                                    Leica Mycrosystems, Cambridge, UK  
Olympus BX50                                    Olympus Microscopy, Hamburg, 
Germany 
TaqMan Sequence Detection System  
 
ABI prism ™ 7700 sequence detector            PE Biosystems, Weiterstadt, Germany 
RTPCR 
 
Light Cycler 480     Roche, Germany 
 
3.2. Other Equipments 
Cryostat RM2155    Leica Microsystems, Bensheim, 
Germany 
Cryostat CM 3000                                          Leica Microsystems, Bensheim, 
Germany 
Digital camera DC 300F   Leica Microsystems, Cambridge, UK 
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Glucometer Accu check sensor  Roche, Mannheim, Germany 
Homogenizer ULTRA-TURRAX T25 IKA GmbH, Staufen, Germany  
Microtome HM 340E    Microm, Heidelberg, Germany 
pH meter WTW     WTW GmbH, Weilheim, Germany 
Thermomixer 5436    Eppendorf, Hamburg, Germany 
Vortex Genie 2™                                             Bender&Hobein AG, Zurich, 
Switzerland 
Water bath HI 1210      Leica Microsystems, Bensheim, 
Germany 
 
3.3. Chemicals and reagents 
Chemicals for the molecular biology techniques 
RNeasy Mini Kit   Qiagen GmbH, Hilden, Germany 
RT-PCR primers                                  PE Biosystems, Weiterstadt, Germany 
      Metbion, Martinstreid, Germany 
Elisa Kits  
mouse RANTES/CCL5                       R &D Systems, Minneapolis, MN, 
USA 
mouse IL6     R &D Systems, Minneapolis, MN, 
USA 
mouse IP 10     R &D Systems, Minneapolis, MN, 
USA 
mouse MCP-1     R &D Systems, Minneapolis, MN, 
USA 
mouse Albumin     Bethyl Laboratories, TX, USA 
 
Cell culture  
DMEM-medium                                              Biochrom KG, Berlin, Germany  
RPMI-1640 medium     GIBCO/Invitrogen, Paisley, Scotland, 
UK 
FSC       Biochrom KG, Berlin, Germany 
Dulbecco’s PBS (1×)      PAA Laboratories GmbH, 
Cölbe,Germany 
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Trypsine/EDTA (1×)      PAA Laboratories GmbH, 
Cölbe,Germany 
Penicillin/Streptomycin (100×)   PAA Laboratories GmbH, 
Cölbe,Germany 
 
Antibodies  
rat anti-F4/80      Serotec, Oxford, UK 
anti-Ki-67      Dianova, Hamburg, Germany 
anti-ssDNA        Chemicon, Hofheim, Germany 
anti-mMECA-32      University of Iowa, Hybridoma Bank, 
USA 
anti-mCCL5       PeproTech, Rocky Hill, NJ, USA 
goat anti-fibronectin      Santa Cruz, Heidelberg, Germany 
rat anti-Mac2      Cederlane, Ontario, Canada 
anti-ERHR3       DPC Biermann, Bad Nauheim, 
Germany 
anti-CD3       BD Pharmingen, Hamburg, Germany 
mouse F4/80 FITC conjugated   Caltag Laboratories, Bulingame, CA, 
USA 
mouse anti CXCL12  
mouse anti CXCL12 FITC conjugated 
R &D Systems, Minneapolis, 
MN, USA mouse anti WT1 PE conjugated 
mouse anti CXCR4 
mouse anti CD45 
 
Chemicals  
Aceton                                                            Merck, Darmstadt, Germany  
AEC Substrat Packung                                   Biogenex, San Ramon, USA  
Bovines Serum Albumin                                Roche Diagnostics, Mannheim, 
Germany 
DEPC                                                              Fluka, Buchs, Switzerland 
DMSO                                                             Merck, Darmstadt, Germany 
Diluent C for PKH26 dye                                Sigma-Aldrich Chemicals, Germany  
EDTA                                                              Calbiochem, SanDiego, USA 
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Eosin                                                                Sigma, Deisenhofen, Germany 
Ethanol                                                             Merck, Darmstadt, Germany 
Formalin                                                           Merck, Darmstadt, Germany  
Hydroxyethyl cellulose                                    Sigma-Aldrich, Steinheim, Germany 
HCl (5N)                                                           Merck, Darmstadt, Germany 
Isopropanol                                                       Merck, Darmstadt, Germany 
Calcium chloride                                               Merck, Darmstadt, Germany  
Calcium dihydrogenphosphate                          Merck, Darmstadt, Germany  
Calcium hydroxide                                            Merck, Darmstadt, Germany 
MACS-Buffer                                                   Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Beta mercapto ethanol                                     Roth, Karlsruhe, Germany 
Sodium acetate                                                 Merck, Darmstadt, Germany  
Sodium chloride                                               Merck, Darmstadt, Germany 
Sodium citrate                                                  Merck, Darmstadt, Germany 
Sodium dihydrogenphosphate                          Merck, Darmstadt, Germany 
Penicillin                                                           Sigma, Deisenhofen, Germany 
Roti-Aqua-Phenol                                             Carl Roth GmbH, Karlsruhe, 
Germany 
Streptomycin                                                      Sigma, Deisenhofen, Germany 
Tissue Freezing Medium                                    Leica, Nussloch, Germany 
Trypan Blue                                                        Sigma, Deisenhofen, Germany 
Oxygenated water                                               DAKO, Hamburg, Germany  
Xylol                                                                   Merck, Darmstadt, Germany  
 
3.4. Miscellaneous 
Anti-FITC MicroBeads                 Miltenyi Biotec, Bergish Gladbach, 
Germany 
CellTiter 96 Proliferation Assay                        Promega, Mannheim, Germany 
Fluorescence-labeled microspheres                   Molecular Probes™/Invitrogen 
GmbH, 
(0.96 m FluoSpheres)       Karlsuhe, Germany 
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LS+/VS+ Positive selection columns (MACS)    Miltenyi Biotec, Bergish Gladbach, 
Germany 
PKH26 Red Fluorescent Cell Linker kit             Sigma-Aldrich Chemicals, 
Steinheim, Germany 
Preseparation filters         Miltenyi Biotec, Bergish Gladbach, 
Germany 
SuperFrost Plus microscope slides                   Menzel-Gläser, Braunschweig, 
Germany 
Silver Impregnation Kit         Bio-Optica, Milano, Italy 
Needles            BD Drogheda, Ireland 
Pipette’s tip 1-1000μL                                          Eppendorf, Hamburg, Germany 
Syringes                                                                Becton Dickinson GmbH, 
Heidelberg, Germany 
Plastic histocasettes          NeoLab, Heidelberg, Germany 
Tissue culture dishes  Ø 100x20mm        TPP, Trasadingen, Switzerland 
Tissue culture dishes  Ø 150x20mm         TPP, Trasadingen, Switzerland 
Tissue culture dishes  Ø 35x10mm         Becton Dickinson, Franklin Lakes, 
NJ, USA 
Tissue culture flasks 150 cm2          TPP, Trasadingen, Switzerland 
Tubes 15 and 50 mL           TPP, Trasadingen, Switzerland 
Tubes 1.5 and 2 mL           TPP, Trasadingen, Switzerland 
 All other reagents were of analytical grade and are commercially available from 
Invitrogen, SIGMA or ROTH. 
 
3.5 Experimental procedures 
3.5.1. Animals 
Male, 5 week old C57BLKS db/db or C57BLKS wild-type mice were obtained from 
Taconic (Ry, Denmark) and were housed in filter top cages with a 12 hour dark/light 
cycle. All mice had unlimited access to food (Sniff, Soest, Germany) and water for 
the complete duration of the study. Cages, bedding, nestles, food, and water were 
sterilized by autoclaving before use. All experimental procedures were performed 
according to the German animal care and ethics legislation and had been approved 
by the local government authorities. 
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3.5.2. Animal model  
 
Db/db mice uninephrectomy: At the age of 6 weeks db/db and wild-type mice 
underwent uninephrectomy (1K mice) or sham surgery (2K mice) performed under 
general anesthesia using isoflurane (Harvard Anesthesia system, UK). Anesthetized 
mice were positioned laterally on the operation bed using adhesive tapes. Under 
deep anesthesia a flank incision of about 1-1.5 cm was made on the dorsolateral side 
just below the thorasic cage so are to reach kidney easily. A silk suture (2-0) was 
passed around the right kidney and after tying off all blood vessels and ureter the 
kidney was rapidly excised out using a curved scissors. In sham group of mice only 
incision was made and kidney was left as such. Skin incision was closed with silk 
suture and wound clamps (Figure 7). After surgery all mice received analgesic (1 
drop of Novaminsulfon, Ratiopharm GmbH, Germany, 1:200, orally administered). 
 
 
 
B  A  
 
 
 
 
 
C D  
 
 
 
 
 
 
Figure 7: Pictures showing surgical procedure for uninephrectomy in mice. A: Making flank 
incision.  B: Tying off the vessels and ureter with silk suture. C: Excision of the kidney after ligation. 
D: Wound closing with silk suture and wound clamps. 
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3.5.3. Drugs and formulations 
 
To achieve CCL2 and CXCL12 antagonism we used a RNA-aptamers (Spiegelmer), 
a patented technology of NOXXON Pharma (Berlin). RNA-aptamer bind to the 
active site of target chemokines and makes them biologically non-functional.  
 
An aptamer is a nucleic acid structure that can bind to a target molecule 
conceptually similar to an antibody that recognizes an antigen. Aptamers have 
binding characteristics similar to peptides or antibodies, with affinities in the low 
nanomolar to the picomolar range. However, there are several drawbacks to 
aptamers as useful therapeutic products. As relatively small molecules, aptamers 
demonstrate circulating half-lives in vivo in the order of minutes. This situation can 
be addressed by attaching large inert molecules to aptamers (e.g. polyethylene 
glycol) to reduce their elimination via the kidney and increase their presence in the 
circulation. Still, aptamers, as natural nucleic acid polymers, are prone to rapid 
degradation by nucleases that are present in all tissues in the body.  
 
Spiegelmers are biostable aptamers, have all of the diverse characteristics of 
aptamers but possess a structure that prevents enzymatic degradation. While 
aptamers are created from the natural D-nucleotides, which are recognized by the 
nucleic acid degrading enzymes, Spiegelmers are synthesized as the mirror image L-
oligonucleotide and are not degraded by any nucleases since there are no such 
enzymes in the body capable of interacting with these unnatural molecules173. 
Spiegelmer technology is based on the simple concept that if an aptamer binds its 
natural target, the mirror image of the aptamer will identically bind the mirror image 
of the natural target (Figure 8). The process of aptamer selection is carried out 
against the mirror image target protein, an aptamer against this unnatural mirror 
image is obtained. More important, this Spiegelmer is now resistant to nuclease 
degradation. Spiegelmers should not be confused with antisense RNAs in that they 
do not directly interfere with transcription or translation of their target molecules 173. 
They are designed to bind specifically to extracellular proteins, either a receptor or 
its ligand, similar to the behavior of a monoclonal antibody, aptamer or peptide. 
Spiegelmers appear to be non-immunogenic, even under the most inductive 
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conditions for antibody formation in rabbits. These molecules are termed 
“Spiegelmer” from the German word “Spiegel” meaning “mirror” 
(www.noxxonpharma.com). 
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epresentation of Spiegelmer generation.  
(Figure taken from www.noxxonpharma.com ) 
 
 
Study 1: 
CCL2 / MCP-1 antagonist: mNoxE36 (Anti-Ccl2 Spiegelmer)  
Ribonucleotide sequence:  
5’- GGCGACAUUGGUUGGGCAUGAGGCGAGGCCCUUUGAU 
GAAUCCGCGGCCA-3’-40 kDa PEG 
Spiegelmer was dissolved in isotonic 5 % glucose solution for administration to 
mice. 
 
Control Spiegelmer: Poc (scrambled sequence of RNA) 
Ribonucleotide sequence:  
5’-UAAGGAAACUCGGUCUGAUGCGGUAGCGCUGUGCAGA 
GCU-3’-40 kDa PEG 
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Control Spiegelmer was dissolved in isotonic 5 % glucose solution for 
administration to mice. 
 
Vehicle: 5% glucose solution was administed to vehicle group at the same 
concentration.  
 
Study 2: 
WM 7671: Orally bioavailable CCR2 and CCR5 dual antagonist  
(Was obtained from Novartis Pharma.) 
Dissolved in double distilled water and was administered orally  
 
WM 7390: Orally bioavailable CCR2 and CCR5 dual antagonist  
(Was obtained from Novartis Pharma.) 
Dissolved in double distilled water and was administered orally  
 
Vehicle: Distilled water 
 
Study 3: 
CXCL12 / SDF antagonist: mNOX-A12 (Anti-CXCL12 Spiegelmer):  
Ribonucleotide sequence:  
PEG 40 kDa-5'-GCGUGGUGUGAUCUAGAUGUAU UGGCUGAUCCUAGU 
CAGGUACGC -3'  
(5’-terminally modified with 40-kDa branched polyethylene glycol)  
Spiegelmer was dissolved in isotonic 5 % glucose solution for administration to 
mice. 
 
Control Spiegelmer: revmNOX-A12  
Ribonucleotide sequence: reversed sequence of nucleotide as that of active 
Spiegelmer was used - 5’-terminally modified with 40-kDa branched polyethylene 
glycol. 
 
Vehicle: 5% glucose solution 
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3.5.4. Experimental designs 
 
Study 1: 
6 week 12 week 16 week 20 week                   24 week
Treatment for 3 months 
• Vehicle (5% glucose) 
• revmNOX-E36 
• mNOX-E36 
Blood glucose measurement, Blood samples, Urine 
samples collected every 2 weeks.
6 wks Old mice
Uninephrectomy
Animals scarificed:
Blood samples collected
Kindeny isolated for;
Histopathology
Immunohistochemistry
RNA 
Treatment for 2  months 
• mNOX-E36 
Treatment for 1  months 
• mNOX-E36 
dn y
Poc
 
Study 2: 
 
6 week 12 week 16 week 20 week 24 week
Mice treated with antagonists starting from 20th weeks of age till 
24 week.
Blood glucose measurement, Blood samples, Urine samples 
collected every 2 weeks (20th, 22nd and 24th week)
Groups and treatment duration:
Vehicle treated: From 20th week to 24th week
WM 7671: From 20th week to 24th week                     
WM 7390: From 20th week to 24th week
6 wks Old mice
Uninephrectomy
Animals scarificed:
Blood samples collected
Kidney isolated for;
Histopathology
Immunohistochemistry
RNA 
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Study 3: 
ma 
bes and were stored at -20 0C until used for different biochemical 
stimations. 
 
rmany). Small blood 
amples were withdrawn by cutting tail tip from each mouse. 
 
6 wks Old mice
Uninephrectomy
 
 
3.5.5. Blood and urine sample collection 
Small blood samples (around 100 ul) were collected under isoflurane anesthesia in 
microcentrifuge tubes containing EDTA (10µl of 0.5 M solution per 200µl of 
blood). Collected blood samples were centrifuged at 8000 rpm for 5 min and plas
was separated and stored at -20 0C until used for different cytokine estimations.  
Urine samples were collected every alternate week from each mouse in micro 
centrifuge tu
e
3.5.6. Body weight and blood glucose 
Animals were weighed every week and blood glucose levels were monitored every 
alternate week using glucometer (Accu Check, Roche, Ge
s
6 week 12 week 16 week 20 week 24 week
Mice treated with antagonists starting from 
16th weeks of age till 24 week.
Blood glucose measurement, Blood 
samples, Urine samples collected every 2 
weeks.
Groups : From 16th week to 24th week
• Vehicle (5% glucose) 
• revmNOX-A12 
• mNOX-A12
Animals scarificed:
Blood samples collected
Kidney isolated for;
Histopathology
Immunohistochemistry
RNA 
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3.5.7. Urinary albumin  
Urinary albumin levels were determined using albumin Elisa kit from Bethyl 
laboratories following manufacturer’s instructions. Generally albumin levels in urine 
samples from db/db mice were quite high, so urine samples were diluted 1000 to 
1500 times with water before estimation. In short, capture antibody (Anti-Mouse 
albumin, 1:100 dilution) was coated on polyethylene flat bottom 96 well plates 
(nunc plates) using carbonate-bicarbonate (pH 9.6) coating buffer. After overnight 
incubation of the capture antibody at 4 0C, plate was washed 3 times with wash 
buffer (Tris NaCl with Tween 20) and blocked with blocking solution (Tris, NaCl 
with 1% BSA, pH 8) at room temperature for 1 hour. After blocking was over the 
plate was washed 3 to 5 times with wash buffer and then diluted samples / standards 
were added in respective wells and further incubated for 1 hour. After incubation 
was over each well was washed 5 times with wash buffer and diluted HRP-
conjugated detection antibody (using the suggested dilution) was added and the plate 
was incubated in dark for further 1 hour. After HRP-conjugate incubation was over 
each well was washed 5 to 7 times with wash buffer and TMB reagent (freshly 
prepared by mixing equal volumes of two substrate reagents) was added and 
incubated in dark till colour reaction was completed followed by addition of stop 
solution (2 M H2SO4). The absorbance was read at 450 nm within 10 min of stop 
solution addition. The albumin content in each sample was determined using the 
equation of regression line generated by plotting absorbance of different standards 
against their known concentrations. 
 
3.5.8. Urinary creatinine measurement 
Urinary creatinine levels were measured using enzymatic reaction (Jaffe’ reaction 
using biochemical kit from Diasys). Urine samples were diluted 5 to 10 times 
(depending on the expected concentration range) with distilled water. Different 
dilutions of standard were prepared using the stock provided with the kit. Working 
monoreagent was prepared by mixing 4 part of reagent 1 (R1) and 1 part of reagent 
2 (R2) provided with the kit. 10 µl of each of the diluted samples and standards were 
added to a 96 well plate with flat bottom (Nunc maxisorb plate). 200 µl of 
monoreagent was added to each well and absorbance for was read at 490 nm 
immediately after and 1 (A1) and 2 (A2) min of addition using elisa plate reader. 
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The change in absorbance (Δ A) was calculated   as Δ A = [(A2 – A1) sample or 
standard] – [(A2 – A1) blank]. And creatinine content of samples was calculated as: 
 
Creatinine (mg/dl) = ΔA sample /ΔA standard * Concentration of standard (mg/dl) 
 
3.5.9. Urinary albumin to creatinine ratio  
Urinary albumin to creatinine ratio was calculated after converting values for 
albumin and creatinine to similar units (mg/dl). Albumin content for each sample 
calculated (mg/dl) was divided by creatinine content (mg/dl) for the same sample.  
 
3.5.10. Cytokines 
All cytokine levels in serum samples obtained from mice or supernatant collected 
from in-vitro cells stimulations were estimated using ELISA kits following the 
manufacturer’s instructions. 
 
3.5.10.1. CCL2 measurement 
CCL2 levels in serum samples were measured using a commercially available Elisa 
kit (BD Biosciences, Cat: 555260). Polyethylene 96 well plate was coated with 100 
µl of capture antibody (Anti-Mouse CCL2, 1: 250 dilution) using coating buffer 
(Phosphate buffer, pH 6.5), after over night incubation at 4 0C. Each well was 
washed 3 time with wash buffer (PBS with Tween- 20) and plate was blocked using 
assay diluent (PBS with 10 % FBS) for further 1 hour at room temperature. Each 
well was washed 3 times and prepared standard (ranging from 1000 to 15.6 pg/ml, 
prepared by serial dilution of the stock provided) and diluted serum samples (20 
times diluted in assay diluant) were added to respective well and incubated at room 
temperature for further 2 hours. After sample incubation was over each well was 
washed 5 times with wash buffer using elisa plate washer and 100 µl of HRP-
Conjugated detection antibody (1:250 times diluted in assay diluant) and incubated 
at room temperature in dark for further 1 hour. After incubation was over each well 
was washed 7 times with wash buffer and 100 µl of TMB substrate solution (freshly 
prepared) was added and incubated for 20 to 30 min followed by addition of stop 
solution (2 M H2SO4) and absorbance was read at 450 nm within 10 min of stop 
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solution addtion. CCL2 level in each sample was calculated using the equation of 
regression line generated with by plotting absorbance of different standards against 
their known concentrations. 
 
3.5.10.2. CXCL12 measurement 
CXCL12 levels in serum and cell culture supernatant samples were determined 
using Elisa. Animal group treated with anti-CXCL12 Spiegelmer were expected to 
have significantly elevated CXCL12 levels, samples from Spiegelmer treated group 
were diluted 1000 times with assay diluant. Capture antibody (Anti-mouse CXCL12, 
8 µg/ml) was coated on polyethylene flat bottom 96 well plates (nunc plates) using 
carbonate-bicarbonate (pH 9.6) coating buffer. After overnight incubation of capture 
antibody at 4 0C, plate was washed 3 times with wash buffer (Tris NaCl with Tween 
20) and blocked with blocking solution (Tris, NaCl with 1% BSA, pH 8) at room 
temperature for 1 hour. After blocking was over plate was washed 5 times with wash 
buffer and then diluted samples or standards were added in respective wells and 
further incubated for 2 hour. After incubation was over each well was washed 5 
times with wash buffer and diluted detection antibody (biotinylated anti-mouse 
antibody) was added and the plate was incubated for further 1 hour. After incubation 
was over each well was washed 3 times with wash buffer and HRP (using the 
suggested dilution 1: 250) was added and plate was incubated in dark for further 30 
min. After HRP incubation was over each well was washed 5 times with wash buffer 
and TMB reagent (freshly prepared by mixing equal volumes of two substrate 
reagents) was added and incubated in dark till colour reaction was completed 
followed by addition of stop solution (2 M H2SO4) and absorbance was read at 450 
nm within 10 min. CXCL12 content in each sample was determined using the 
equation of regression line generated with by plotting absorbance of different 
standards against their known concentrations. 
 
3.5.11. Glomerular filtration rate determination 
Glomerular filtration rate in conscious mice was determined using Fluorescein 
Isothiocyanate-inulin (FITC-inulin) clearance from plasma after single bolus 
intravenous injection. In short, FITC-inulin was dissolved in 0.9% NaCl facilitated 
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by heating at 65 0C so as to get a 5 % solution.  Animals were anesthetized using 
isoflurane for short duration, and FITC-inulin (5%) solution was rapidly injected 
retroorbitally (3.74 ul/gm body weight). Blood samples were drawn at different time 
point (3, 7, 10, 15, 35, 55 and 75 minutes post inulin injection). Blood samples were 
centrifuged at 8000 rpm for 5 min and plasma was separated. Each plasma sample 
was buffered to pH 7.4 by mixing 10 µl of plasma with 40 µl of 500 mM HEPES 
buffer (pH 7.4) in 96 well plate. Fluorescence was determined using excitation filter 
having wave length of 485 nm while read filter was set at wave length of 535 nm. 
For GFR calculation two-compartment clearance was employed. In two 
compartment model the initial, rapid decay phase represents redistribution of tracer 
from the intravascular compartment to extracellular fluid. Later, slower decay in 
concentration of the tracer due to systemic clearance from plasma predominates. At 
any given time (tx), the plasma concentration of the tracer (Y) can be calculated as  
 
Y = Ae-αtx +Be-βtx  + Plateau 
Where, 
Y is plasma concentration of tracer 
A is y-intercept of fast decay rate (SPAN1) 
B is y-intercept of slow decay rate (SAPN2) 
α is fast decay rate constant 
β is slow decay rate constant 
 
These parameters were calculated using non-linear curve-fitting program (GraphPad 
Prism) followed by exponential two-phase decay with plateau set as zero. 
GFR was calculated as:  
GFR = I / (A/α +B/β) 
Calculated GFR was reported as ml/min and was expressed as mean ± SEM for each 
group. 
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3.5.12. Fluroscence activated cell sorting  
3.5.12.1. Kidney cells isolation for FACS 
 Isolated kidneys were smashed in to small pieces using scalpel in a plate 
containing Paris-buffer (3ml) on ice and was transferred to 10 ml Falcon tube 
with ice cold Paris-buffer.  
 Tube was then centrifuged at 1200 rcf for 5 minutes at 4 0C.  
 Supernatant was discarded and pellet was re-suspended in 10 ml ice cold 
HBSS (with Ca, Mg) 
 Centrifuged at 1200 rcf for 5 minutes at 4 0C 
 Supernatant was discarded and pellet was digested with Collagenase/DNAse 
solution (5 ml preheated Collagenase/DNAse solution) and was incubated for 
20 min at 37 0C with through mixing in between. 
 Centrifuged at 1200 rcf for 5 minutes at room temperature. 
 Supernatant was discarded and pellet was washed two times in 10 ml ice cold 
HBSS (with Ca, Mg) each time centrifuged at 1200 rcf for 5 minutes at 4 0C 
and supernatant was discarded. 
 Pellet was re-suspended in 5ml of 2mM EDTA in HBSS (without Ca, Mg) and 
was incubated for 20 min at 37 0C. 
 Centrifuged at 400 rcf (30g) for 5 minutes at 4 0C. 
 Pipette the supernatant in new cooled Falcon tube kept on ice (preserve this 
supernatant) and process the remaining pellet. 
 Re-digested the remaining pellet with Collagenase (5ml preheated Collagenase 
solution was added) and was incubated at 37 0C for 20 min with through 
mixing in between. 
 Digested pellet was transferred to ice place, cooled down on ice, then whole 
suspension was pressed through 19G needle twice, followed by 26G and 
finally was pressed through 30G needle and was mixed with the supernatant in 
Falcon (stored previously). 
 Centrifuged at 1200 rcf for 5 minutes at room temperature and supernatant was 
discarded. 
 Pellet was re-suspended in 10 ml ice cold PBS (without Ca, Mg) and 
centrifuged at 1200 rpm for 5 min at 4 0C, supernatant was discarded. 
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 Pellet was dissolved in FACS-buffer (DPBS + 0.2 % BSA + 0.1 % Na Azide) 
and was passed through 70 um nylon filter (which was rinsed previously with 
1ml PBS), filtrate was collected in new Falcon on ice, volume was made up to 
10 ml with PBS. 
 Centrifuged at 1500 rpm at 4 0C for 5 min and supernatant was discarded.  
 Obtained pellet was re-suspended in 200 to 500 ul (depending on pellet size) of 
FACS- buffer and processed for staining with different antibodies. 
 
3.5.12.2. Staining for FACS 
Sufficient number of isolated kidney cells (suspended in FACS buffer) from each 
sample were transferred to FACS-tubes containing master mix serum (5 ul of rat 
serum and 5 ul of mouse serum) and incubated for 10 min. Required antibodies were 
prepared and added to the above mixture and incubated at room temperature for 
further 60 min in dark. After antibodies (cKit, Sca or CXCR4) incubation FACS 
buffer (2 ml) was added and vortexed thoroughly, centrifuged at 1200 rpm for 5 min 
at 4 0C, this procedure was repeated twice (two washes) and finally pellet was 
suspended in 300 µl of FACS buffer and was processed for FACS analysis.  
 
3.5.12.3. Preparation of blood for FACS 
Blood samples were collected in micro-centrifuge tubes containing EDTA (5 µl per 
100 µl of blood). 100 µl of blood samples were transferred to FACS tubes 
containing serum master mix (5 µl of rat serum + 5 µl of mouse serum) and 
incubated for 10 min at room temperature. Different antibodies (cKit, Sca or 
CXCR4) were added to respective tubes (1.4 ul per AB) and were incubated in dark 
for further 60 min. After antibody incubation 2 ml of diluted lysis buffer (1:10 
times) (BD FACS lysis solution, 349202) was added to each tube vortexed and 
incubated for further 10 min. Then tubes were centrifuged at 1200 rpm for 4 min at 4 
0C. Supernatant was discarded and washed twice with FACS buffer followed by 
centrifugation at 1200 rpm for 4 min at 4 0C, finally supernatant was sucked so that 
last 300 µl of FACS buffer remains in the tube. 
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3.5.13. Immunostaining  
For immunohistological studies middle part of kidney from each mouse were fixed 
in formalin (10 % in PBS or Saline) over night and processed using tissue processors 
(Leica) and paraffin blocks were prepared. 2 m thick paraffin-embedded sections 
were cut. De-paraffinization was carried out using xylene (3 * 5 min) followed by 
re-hydration, which was carried out by incubating the sections in 100% absolute 
ethanol (3 * 3 min), 95% ethanol (2 * 3 min) and 70% ethanol (1 * 3 min) followed 
by washing with PBS (2 * 5 min). Blocking endogenous peroxidase was carried out 
by incubating sections in H2O2 and methanol mixture (20 ml of 30% H202 in 180ml 
of methanol) for 20 min in dark followed by washing in PBS (2* 5min). For 
unmasking of antigen sections were dipped in antigen unmasking solution (3 ml of 
antigen unmasking solution + 300 ml of distilled water) and cooked in microwave 
for total of 10 min (4*2.5 min, every 2.5 min water level was checked and made up 
to the initial levels with distilled water every time). After microwave cooking 
sections were cooled to room temperature for 20 min and washed with PBS. 
Blocking endogenous biotin was carried out by incubating sections with one drop of 
Avidin (Vector) for 15 min followed by incubation with Biotin (Vector) for further 
15 min. After the incubation was over sections were washed with PBS (2* 5 min).  
 
Sections were incubated with different primary antibodies either for 1 hour at room 
temperature of over night at 4 0C in a wet chamber followed by wash with PBS (2* 5 
min). After washing sections were incubated with biotinylated secondary antibodies 
(1:300, dilution in PBS) for 30 min followed by wash with PBS (2* 5 min). 
Substrate solution (ABC solution, Vector) was and sections were incubated for 30 
min at room temperature in a wet chamber followed by wash with PBS (1* 5 min).  
Tris (1* 5 min) and sections were stained for DAB followed by counter staining 
with methyl green (Fluka). Then sections were washed with alcohol (96 %) to 
remove excess stain and xylene. Sections were dried and mounted with VectaMount 
(Vector).  
 
The following rat and rabbit antibodies were used as primary antibodies: rat anti-
Mac2 (glomerular macrophages, Cederlane, Ontario, Canada, 1:50), rat anti-F4/80 
(macrophages, Serotec, Oxford, UK, 1:50), anti-Ki-67 (cell proliferation, Dianova, 
Hamburg, Germany, 1:25), anti-mMECA-32 (endothelial cells, Iowa Hybridoma 
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Bank, USA,1:5), anti-m CXCL12 (R&D System, 1: 100) and anti-m SMA-α (1:50). 
For each immuno staining negative controls staining was performed by incubation 
with a respective isotype antibody instead of primary antibody. 
 
3.5.14. Periodic acid Schiff staining 
Formalin-fixed tissues were processed using tissue processors (Leica) and paraffin 
blocks were prepared. 2 m thick paraffin-embedded sections were cut. De-
paraffinization was carried out using xylene (3 * 5 min) followed by re-hydration by 
incubating the sections in 100% absolute ethanol (3 * 3 min), 95% ethanol (2 * 3 
min) and 70% ethanol (1 * 3 min) followed by washing with distilled water (2 * 5 
min). Re-hydrated sections were incubated with Periodic acid (2 % in distilled 
water) for 5 min followed by washing with distilled water (1* 5 min). Then sections 
were incubated with Schiff solution for 20 min at room temperature followed by 
washing with tap water (1* 7 min) and counter staining with Hematoxylin solution 
(1* 2 min). This was followed by washing with tap water (1* 5 min) and finally 
sections were dipped in alcohol 90% and dried and closed with cover slips. 
 
3.5.15. Silver staining 
Formalin fixed tissue were processed using tissue processors (Leica) and paraffin 
blocks were prepared. 2 m thick paraffin-embedded sections were cut. De-
paraffinization was carried out using xylene (3 * 5 min) followed by re-hydration, 
which was carried out by incubating the sections in 100% absolute ethanol (3 * 3 
min), 95% ethanol (2 * 3 min) and 70% ethanol (1 * 3 min) followed by washing 
with distilled water (2 * 5 min). Re-hydrated sections were processed for silver 
staining using tissue section staining kit from Bio-Optica (Milano, Italy). In short the 
principle involves initial oxidation of sections with potassium permanganate 
followed by treatment with trivalent iron. The bound iron is then replaced by silver 
using ammonical silver solution.  
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3.5.16. Histopathological evaluations 
3.5.16.1. PAS staining: For quantitative analysis 2 m sections were stained with 
periodic acid-Schiff reagent. Glomerular sclerotic lesions were assessed using a semi 
quantitative score by a blinded observer as follows: 
0 = no lesion,  
1 = <25% sclerotic 
2 = 25-49% sclerotic 
3 = 50-74% sclerotic 
4 = 75-100% sclerotic 
From each section 15 glomeruli were analyzed. All sections were quantified in each 
group and were expressed as percentage of glomeruli with each score (mean ± 
SEM).  
 
3.5.16.2. Silver staining: Silver staining was performed on 2 m sections following 
manufacturer’s instructions (Bio-Optica, Milano, Italy).The indices for interstitial 
volume, interstitial collagen deposition, tubular cell damage, and tubular dilatation 
were evaluated manually by superposing a grid containing 100 (10 x 10) sampling 
points on photographs of 10 non-overlapping cortical high power fields of silver-
stained tissue (200 X) of each kidney. 
 
3.5.16.3. Mac2 staining: Number of infiltrated macrophages in glomeruli as well as 
in interstitium were counted in sections stained with Mac2 (pan marker for 
macrophage) antibodies. Mac2 positive cells were counted manually in 15 glomeruli 
or 15 non-over lapping high power fields interstitium for each section and were 
presented as mean ± standard error of mean for respective groups.  
 
3.5.16.4. Ki67 staining: Number of proliferating cells within glomeruli were 
evaluated using Ki 67 staining. For quantification Ki67 positive cells were counted 
manually in 15 glomeruli in each section and presented as mean ± standard error of 
mean for respective groups.   
 
3.5.16.5. SMA-α staining: For tissue fibrosis assessment sections were stained with 
SMA-α anti-body. For quantification a semi-quantitative method was employed, in 
short each glomerulus was scored from 0 (least positive) to 4 (most positive cells) by 
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a blinded observer. For each section 20 glomeruli were scored and finally presented 
as mean ± standard error of mean for respective groups.  
 
3.5.16.6. Meca32 staining: Number of Meca32 positive endothelial cells were 
calculated manually in 10 non-overlapping high power fields (200X). Positive cells 
were counted manually using Adobe photo shop software after capturing images 
from all sections (10 images per section). Results are presented as ± minus standard 
error of mean for respective groups. 
 
3.5.17. RNA analysis 
3.5.17.1. RNA isolation: When animals were sacrificed on termination of the study, 
small parts of kidney from each mouse were preserved in RNA-later and stored at -
20 0C until processed for RNA isolation. RNA isolation was carried out using RNA 
isolation kit from Qiagen (Germany). In short, tissues (30 mg) preserved in RNA-
later were homogenized using blade homogenizer for 30 seconds at 14500 rpm in 
lysis buffer (600 µl) containing β-mercaptoethanol (10 µl/ml). The homogenate was 
centrifuged at 15000 rpm for 3 min. and 350 µl of supernatant was transferred to 
fresh DEPC-treated tube to this equal amount (350 µl) of 70 % ethanol was added 
and whole mixture was loaded on RNA column and processed for RNA isolation as 
per the manufacturer’s instruction. Isolated RNA was stored at -80 °C until further 
used. 
 
3.5.17.2. RNA quantification and purity check: For quantification isolated RNA 
samples were diluted in DEPC water (2 μl of RNA + 98 μl of DEPC water, 50 times 
dilution) and absorbance was measured at two wavelengths as 260 nm and 280 nm.  
 
Amount of RNA (μg/μl) = O.D. at 260 nm * 40 * 50 (dilution factor)/ 1000 
 
The ratio of optical densities at 260 nm and 280 nm is an indicator for RNA purity 
(indicative of protein contamination in the RNA samples). Only samples with a ratio 
of 1.8 or more were considered to be of acceptable quality.  
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3.5.17.3. RNA integrity check: Further quality check (if necessary) was performed 
using a denaturing RNA gel. In short 2 % Agarose gel with Ethidium-bromide was 
casted, RNA samples were mixed with RNA loading buffer (4:1 ratio) (Sigma) and 
were loaded on the gel. Electrophoresis was carried out at constant volt (70-100 V) 
using MOBS running buffer for 1 hour and the gel was read on a gel documentation 
apparatus under UV lamp. RNA samples showing a single bright band were 
considered to be of good quality. Loss of RNA integrity could be detected as smear 
formation in the agarose gel (Figure 9). 
 
 
 
 
 
 
 
                              Figure 9: Representative agarose gel for RNA integrity check. 
 
3.5.17.4. cDNA synthesis and real-time RT-PCR (SYBR Green) 
The isolated RNA samples were quantified and processed for cDNA conversion using 
reverse transcriptase II (Invitrogen). RNA samples were diluted in DEPC treated tubes 
with water to get final concentration of 2 μg / 30 μl, to this diluted RNA samples 13.9 
μl of master mix* was added, all tubes were incubated at 42 0C for 1 hour and 30 min 
on thermal shaker. Upon completion of incubation cDNA samples were stored at -20 
°C until used for RT-PCR analysis using SYBR green. 
*The master mix was prepared by mixing 9 μl of 5x buffer (Invitrogen, Karlsruhe, 
Germany), 1 μl of 25 mM dNTP mixture (Amersham Pharmacia Biotech, Freiburg, 
Germany), 2 μl of 0.1 M DTT (Invitrogen, Karlsruhe, Germany), 1 μl of 40U/ μl 
RNasin (Promega, Mannheim, Germany), 0.5 μl of Hexanucleotide (Roche, 
Mannheim, Germany), 1 μl of Superscript (Invitrogen, Karlsruhe, Germany) or ddH2O 
in the case of the control cDNA (RT minus).  
 
The cDNA samples prepared as described above were diluted 1:10 a dilution for the 
real-time RT-PCR. 2 μl of diluted cDNA samples were mixed with SYBR green 
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master mix (10 μl), forward primer, specific for gene of interest (0.6 μl), reverse 
primer specific for gene of interest (0.6 μl), Taq polymerase (0.16 μl) and distilled 
water (6.64 μl). The real-time RT-PCR was performed using Light Cycler480.  
 
For RT-PCR following protocol was used 
Pre-incubation was carried out for 5 minutes at 95 °C so as to activate the polymerase 
and complete de-naturation of cDNA samples. Followed by amplification for 40 
cycles, each comprising of 15 seconds incubation at 95 °C and 45 seconds incubation 
at 60 °C. For melting curve initial 95 °C for 5 seconds followed by 65 °C for 1 min 
with continuous heating was used. The RT-PCR for the reference genes (18S rRNA) 
was carried out under similar conditions. The CT values were calculated using the 
Light Cycler480 and the results were normalized with respective reference gene 
expression for each sample. In all cases controls consisting of ddH2O were negative 
for target or reference genes. All designed SYBR green primers for all genes evaluated 
were obtained from Metabion (Martinsried, Germany).  
 
3.5.17.5. Oligonucleotide primers used for SYBR-Green RT-PCR 
18S         Forward primer: 5'-GCAATTATTCCCCATGAACG-3' 
                      Reverse primer: 5'- AGGGCCTCACTAAACCATCC-3' 
Ccl2         Forward primer: 5'-ATTGGGATCATCTTGCTGGT-3' 
                         Reverse primer: 5'-CCTGCTGTTCACAGTTGCC-3' 
iNos         Forward primer: 5'-TGAAGAAAACCCCTTGTGCT-3' 
                         Reverse primer: 5'-TTCTGTGCTGTCCCAGTGAG-3' 
Cxcl12         Forward primer: 5'-GCGCTCTGCATCAGTGAC-3' 
                         Reverse primer: 5'-TTTCAGATGCTTGACGTTGG-3' 
Arg I         Forward primer: 5'-AGAGATTATCGGAGCGCCTT-3' 
                         Reverse primer: 5'-TTTTTCCAGCAGACCAGCTT-3' 
Mcr1         Forward primer: 5'-ATATATAAACAAGAATGGTGGGCAGT-3' 
                         Reverse primer: 5'-TCCATCCAAATGAATTTCTTATCC-3' 
Mcr2         Forward primer: 5'-GCAAAACCTGCAGAAGCTGT-3' 
                         Reverse primer: 5'-ACCATCTGTCCACCTGAAGC-3' 
Ym1         Forward primer: 5'-TCTGGGTACAAGATCCCTGAA-3' 
                         Reverse primer: 5'-TTTCTCCAGTGTAGCCATCCTT-3' 
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Il10         Forward primer: 5'-ATCGATTTCTCCCCTGTGAA-3' 
                         Reverse primer: 5'-TGTCAAATTCATTCATGGCCT-3' 
Fizz1(Retnla) Forward primer: 5'-CCCTTCTCATCTGCATCTCC-3' 
                         Reverse primer: 5'-CTGGATTGGCAAGAAGTTCC-3' 
 
All primers were procured at concentrations 100 pmol/ul and were used at 10 pmol/ul 
concentrations after dilution with distilled water before use in RT-PCR mixture. 
 
3.5.18. In vitro methods 
3.5.18.1. Culture of murine cells  
The murine macrophage cell line J774 (American Type Culture Collection, Rockville, 
MD, USA) or murine glomerular endothelial cell lines were grown in RPMI 1640 
medium containing 10% heat-inactivated fetal calf serum, penicillin 100 U/ml and 
streptomycin 100μg/ml (complete RPMI medium) under standard culture conditions 
(in an incubator set at 37 °C supplied with 5 % CO2/air). A proximal tubular epithelial 
cell line was maintained in DMEM medium (GIBCO/Invitrogen, Carlsbad, CA, 
USA) containing 10% FCS and 1% penicillin-streptomycin under standard culture 
conditions as described above. Once culture plates were confluent with J774 mouse 
macrophages or proximal tubular epithelial cells (every 24-36 hrs.) were normally 
split into 6 /12 well plate or subcultured according to the following procedure: After 
removing the old medium, cells were washed twice with PBS. Subsequently, the 
appropriate volume of EDTA-trypsin solution was added to the culture flasks and the 
cells were incubated at RT for 5 min. Trypsinization was stopped by adding complete 
medium and cells were re-suspended and transferred to new sterile Falcon tube. Cells 
were centrifuged at 1000 RPM for 3 min at RT, supernatant was discarded and the 
pellet was re-suspended in 5 ml of fresh RPMI or DMEM medium (depending on the 
cell line). For subculturing relatively less number of cells were transferred to new 
culture plates containing fresh media. Before splitting into 6 /12 well plates number of 
cells were counted using Neubauers’ chamber and desired number of cells were 
transferred to each well of 6 /12 well plates containing fresh media and incubated at 
37 ºC for 24 h under standard culture conditions before stimulation with different 
ligands. 
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3.5.18.2. Culture of immortalized murine podocytes 
In order to propagate, podocytes were cultivated at lower temperature (33 ºC)  in 
RPMI 1640 supplemented with 10 % FCS, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin and 10 U/ml of mouse recombinant γ-interferon in 5 % CO2 
atmosphere. For differentiation, podocytes were maintained at higher temperatures 
(38 ºC) without recombinant γ-interferon for at least 2 weeks. Differentiated 
podocyte phenotype were assessed by morphology (large and well spread cells) and 
from time to time by WT1 and nephrin immunofluroscence.    
 
3.5.18.3. Cell freezing and thawing  
At earlier passages large amounts of cells were grown under standard culture 
conditions and were frozen for future use. Cells to be frozen were detached from the 
culture plates and were spun down under sterile conditions for 3 min at 1000 RPM. 
The cell pellet was maintained on ice and carefully re-suspended in cold freezing 
medium (90 % respective culture medium and 10 % DMSO) by pipetting the 
suspension repeatedly up and down. 1.5 ml aliquots were quickly dispensed into 
freezing vials (4 °C). The cells were slowly frozen at –20 °C for 1 h and then at –80 
°C overnight. The next day, all aliquots were transferred to liquid nitrogen. 
 
In order to thaw cells a frozen vial was removed from liquid nitrogen and put in a 
water bath at 37 °C. The cells were then dispensed in 5 ml of warm complete growth 
medium and spun down at 1000 RPM for 5-7 min. Then the old medium was 
removed and the cells were re-suspended in fresh medium and transferred to new 
culture plate. The medium was changed once more after 24 h. 
 
3.5.18.4. Stimulation experiments 
Before stimulation with any ligand all cells splited in 6 /12 well plates for 
stimulation experiments (J774, GENC, MTC or Podocytes) were maintained in 
RPMI 1640 or DMEM supplemented with 1% penicillin-streptomycin and less (1 
%) or no FCS for at least 24 hrs (serum starvation). 
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3.6. Computer programs  
- CellQuest software 
- ABI PRISM Sequence Detection software 1.0 
- Light Cycler 480 Software  
- SPSS for Windows 13.0 
- Graph pad prism 5 
- Endnote plus 9 
- Office XP, 2003 
- Photoshop 7.0, CS 
- Windows 2003 Professional  
 
3.7. Statistical analysis 
Data are presented as mean  SEM. For multiple comparison of groups one way 
ANOVA was used followed by post-hoc Bonferroni`s test, using SigmaStat (Jandel 
Scientific, Erkarath, Germany). Paired Student`s t-test was used for the comparison 
of single groups. A value of p < 0.05 was considered to indicate statistical 
significance.  
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4. Results 
4.1. Animal model validation 
4.1.1. Glomerulosclerosis is aggravated upon uninephrectomy 
There are several animal models that have been described for experimental diabetic 
nephropathy. The most widely accepted animal model for experimental type 2 
diabetic nephropathy is db/db mice. We performed uninephrectomy at early age (6 
weeks of age) which aggravated the development of diabetic nephropathy in db/db 
mice. To validate the development of diabetic nephropathy animals were sacrificed 
at the age of 24 weeks and kidney sections were analysed histochemically.  
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Figure 10 : PAS stains for renal sections. A: PAS stains were scored for the extent of 
glomerulosclerosis from 0-4 as described in methods. From each mouse 15 glomeruli from each renal 
section were graded by that score. The graph illustrates the mean percentage of each score ± SEM 
from all mice in each group (n=9-12). Sham operated mice showed development of mild 
glomerulsclerosis compared to wild type mice. Uninephrectomy was associated with a shift towards 
higher scores of glomerulosclerosis. ** p < 0.01 versus  wild type mice and # p<0.05 verses sham 
operated db/db mice. B: Representative renal sections from 24 weeks old wild type and db/db mice 
stained for periodic acid Schiff (PAS) (magnification 630X).   
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Glomeruli from PAS staining of kidney sections were scored manually as descried 
in materials. Uninephrectomy in db/db mice resulted in a significant increase in the 
percentage of glomeruli with higher scores, indicative of glomerulosclerosis (Figure 
10).   
 
4.1.2. Glomerulosclerosis was associated with macrophage infiltration in kidney 
In order to evaluate contribution of different inflammatory pathways in development 
of diabetic nephropathy. We evaluated kidney sections for number of infiltrating 
macrophages in different compartments. Kidney sections were stained for Mac2 
(marker for macrophages) and sections were quantified manually as described in 
methods section.  
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Figure 11 : Renal sections from 24 week old mice with or without uninephrectomy were stained 
for Mac2. Graphs show the numbers of positive cells in 15 glomeruli (A) or interstitium (B) in wild 
type, sham-operated (2K) and uninephrectomized (1K) db/db mice at 6 months of age. * p < 0.05 
versus  wild type mice and # p<0.05 verses sham operated db/db mice. C: Representative renal 
sections from 24 weeks old wild type and db/db mice stained for Mac2 (magnification 400X). 
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Aggravated glomerulosclerosis in db/db mice upon uninephrectomy was associated 
with increased numbers of infiltrating macrophages in glomeruli (Figure 11). 
 
4.1.3. Uninephrectomy in db/db mice resulted in increased albuminuria and 
decreased glomerular filtration rate 
Development of diabetic nephropathy has been characterized with increased 
albuminuria in different animal models as well as in humans, with associated 
impairment of glomerular filtration rate. Uninephrectomy at early age (6 week) in 
db/db mice resulted in significant increased albuminuria and was associated with 
decreased GFR compared to sham operated mice at the age of 24 week, indicative of 
the development of diabetic nephropathy (Table 3).  
 
Table 3: Effect of uninephrectomy on albuminuria and glomerular filtration rate 
 WT (2K) db/db (2K) db/db (1K) 
 Urinary albumin to creatinine ratio (mg/dl) 0.08 ± 0.02 0.24 ± 0.05 0.32 ± 0.13*
 GFR (ml/min) 385 ± 103 293 ± 74 116 ±  22**
 Body weight (g) 27 ± 0.58 58 ± 2.46 56 ± 2.55 
 Plasma glucose (mg/dl) 142 ± 3.5 414 ±  22 399 ±  25 
WT; wild type, 2K; sham operated, 1K; uninephrectomised, GFR; glomerular filtration rate,  
* p < 0.05, ** p <0.01 compared to sham operated db/db (2K) mice. 
 
4.2. Role of pro-inflammatory chemokines in diabetic nephropathy 
4.2.1. CCL2/MCP-1 blockade at different stages of disease progression  
4.2.1.1. CCL2 levels in serum 
To assess the efficiency of employed Spiegelmer for its biological activity we 
estimated CCL2 levels in serum from all groups. Serum levels of CCL2 were 
significantly (p < 0.05) increased in all groups of mice treated with mNOX-E36 
compared to vehicle of Poc treated mice at 6 months of age, indicating that CCL2-
specific Spiegelmers retain CCL2 in the intravascular compartment (Figure 12). 
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Figure 12: Serum CCL2 levels. CCL2 serum levels were estimated in the serum samples collected 
at the age of 24 weeks from mice of all groups using ELISA. *** p < 0.001 versus  vehicle treated 
mice.  
 
4.2.1.2. CCL2 blockade prevented further increase in urinary albumin to creatinine 
ratio 
Albumin / creatinine ratio is an important clinical parameter for assessment of renal 
disease progression. In diabetic nephritis urinary albumin to creatinine ratio has been 
reported to increases with the progression of kidney inflammation. In our animal 
model of diabetic nephropathy we observed a trend in increase of urinary albumin to 
creatinine ratio over the time. To assess the effect of CCL2 blockade on progression 
of disease we estimated urinary albumin to creatinine ratio at different time points of 
the study. Treatment with a CCL2 antagonist (mNOX-E36) was expected to inhibit 
the progression of renal disease in db/db mice, which can be indicated by the 
reduction of albumin / creatinine ratio, when compared to vehicle or Poc-treated 
groups.  
A subcutaneous administration of CCL2 antagonist mNOX-E36 (50 mg/kg, three 
times per week) for different time lengths [3 to 6 months, 4 to 6 months and 5 to 6 
months] to uninephrectomized db/db mice inhibited further increase in urinary 
albumin/ creatinine ratio compared to Poc-treated group (Figure 13).  
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Figure 13: Urinary albumin to creatinine ratio. Proteinuria was determined after every 2 weeks of 
Spiegelmer injections in uninephrectomized db/db mice treated as indicated. Data represent means of 
urinary albumin/creatinine ratio ± SEM. * p < 0.05 mNOX-E36 versus vehicle treated 1K db/db 
mice. 
 
 
 
 
4.2.1.3. CCL2 blockade inhibited mesangial cell proliferation 
Glomerulosclerosis in diabetic nephropathy is well correlated with mesangial cells 
hyper proliferation and matrix expansion. To assess the effect of CCL2 blockade on 
renal cell proliferation we performed Ki 67 immuno staining of kidney sections from 
all groups as described in materials and methods. Upon treatment with mNOX-E36 
numbers of Ki 67 positive cells in glomeruli were significantly reduced compared to 
vehicle or Poc-treated mice indicative of less proliferation within glomeruli, which 
was consistent with our earlier report 61 (Figure 14).  
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Figure 14: Ki 67 staining of kidney sections. A: Immunohistochemical evaluation of Ki-67 stained 
renal sections from different group of mice as indicated. Date is represented as mean ± SEM ** p < 
0.01 mNOX-E36 versus Poc treated 1K db/db mice.  B: Representative renal sections stained for Ki-
67 in uninephrectomized (1K) db/db, vehicle treated mice, Poc treated, active spiegelmer (mNOX-
E36) treatment started at different stages of disease progression, month 3-6, month 4-5 or month 5-6 
(magnification 400X). 
  
 
4.2.1.4. Macrophage infiltration was inhibited upon CCL2 blockade 
Infiltration of macrophages to renal compartment is considered to be hallmark of 
diabetic nephropathy progression. We tried to inhibit the recruitment of 
macrophages to the kidney by blocking CCL2. Mac2 being a marker for 
macrophages in order to assess number of infiltrated macrophages in different 
compartments of kidney we employed Mac2 staining of paraffin-embedded kidney 
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sections. The numbers of Mac2-positive cells were counted manually. We observed 
a significant reduction in the number of Mac2-positive cells in glomeruli as well as 
in the interstitium in mNOX-E36-treated group as compared to vehicle of Poc-
treated group, which is consistent with our earlier report61. Interestingly, we did not 
observe any difference in percentage reduction of macrophage infiltration in groups 
of mice treated for different time lengths (Figure 15).   
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Figure 15: Renal sections from mice of all groups were stained for Mac2. Graphs shows the 
numbers of positive cells in 15 glomeruli in uninephrectomized (1K) db/db (A) Date is represented as 
mean ± sem * p < 0.05 compared to vehicle treated mice. Representative images from renal sections 
(magnification 630X) (B). 
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4.2.1.5. Improvement of glomerular pathology upon CCL2 blockade 
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Figure 16: PAS staining of renal sections. Renal sections from mice of all groups treated for 
different time lengths as indicated were stained with PAS and scored for the extent of 
glomerulosclerosis (as described in methods). A: The graph illustrates mean percentage of each score 
± SEM from all mice in each group (n=10) *p<0.05 versus Poc treated mice. B: Representative 
images from different groups at the age of 24 weeks stained for PAS (magnification 400X). 
 
Treatment with mNOX-E36 was associated with a significant (p < 0.05) 
improvement of global diabetic glomerulosclerosis in 1K db/db mice compared to 
vehicle or Poc-treated mice. In fact, mNOX-E36 treatment reduced 
glomerulosclerosis in 1K db/db mice to the extent of glomerulosclerosis present in 
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age-matched 2K db/db mice, which is again consistent with our earlier publication61. 
The improvement of glomerulosclerosis in mice treated with mNOX-E36 was found 
to be independent of length of the treatment periods tested (Figure 16). 
 
4.2.1.6. Renal CCL2 mRNA expression 
In order to study whether treatment with mNOX-E36 affects intrarenal inflammation 
in db/db mice, real-time RT-PCR (SYBR green) was performed for the 
proinflammatory chemokine CCL2. We found CCL2 mRNA expression was 
progressively up regulated in kidneys of db/db mice during the progression of renal 
disease. Kidneys of 6-months-old 2K db/db mice showed low CCL2 mRNA 
expression level while early uninephrectomy was associated with a marked increase 
in renal CCL2 mRNA expression in db/db mice at 6 months of age (Figure 17A).  
 
 
0
1e-006
2e-006
3e-006
C57 2K
db/db 2K
db/db 1K
24 week
C
cl
2 
/1
8s
 m
R
N
A
 e
xp
re
ss
io
n
in
 K
id
ne
y,
 M
ea
n 
± 
SE
M
**
                  
0
5e-006
1e-005
Poc            (months 3-6)
mNOX-E36 (months 5-6)
mNOX-E36 (months 3-6)
#
24 week
C
cl
2 
/1
8s
 m
R
N
A
 e
xp
re
ss
io
n
in
 K
id
ne
y,
 M
ea
n 
± 
SE
M
 
A B 
Figure 17: The mRNA expression levels of CCL2. The mRNA expression levels of CCL2 were 
quantified by real-time RT-PCR and corrected for respective 18s rRNA expression levels.  The data 
represented as means ± SEM (n = 3 pooled samples). ** p < 0.01 versus wild type 2K mice, # p<0.05 
versus Poc-treated 1K mice.  
 
 
Treatment with mNOX-E36, from month 5 to month 6 of age reduced total renal 
expression of CCL2 mRNA significantly compared to Poc-treated group. But 
reduction upon mNOX-E36 treatment from month 3 to month 6 of age (the longest 
treated group) was not statistically significant compared to Poc-treated mice (Figure 
17B). 
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4.2.1.7. Effect of CCL2 blockade on glomerular filtration rate 
In this study, the GFR was determined by the ability of db/db mice to excrete FITC-
labelled inulin. Progressing inflammation of the kidneys results in a loss of filtering 
ability and results in decreased glomerular filtration rate (GFR) in diabetic mice. In 
db/db mice, the GFR decreases with age. We observed reduced GFR in db/db mice 
at the age of 24 weeks as compared to age matched wild type mice. Uninephrectomy 
in db/db mice aggravates this process, as we observed significantly reduced GFR in 
uninephrectomised db/db mice compared to age-matched wild type or sham 
operated mice (Figure 18A). All 1K db/db mice groups treated with mNOX-E36 [3 
to 6 months, 4 to 6 months and 5 to 6 months] showed a statistically significant 
(p < 0.01) improvement of GFR compared to the Poc-treated 1K db/db mice (Figure 
18B).  
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Figure 18:  Glomerular filtration rate. Glomerular filtration rate (GFR) was measured by FITC-
inulin clearance kinetics in 6 months old C57BL/6 wild-type mice, sham-operated db/db mice (2K) 
and in uninephrectomized db/db mice (1K) (A) data represent means ± SEM from 4-7 mice, ** 
p<0.01 versus wild type 2K mice. At the end of study glomerular filtration rate (GFR) was measured 
in all groups treated with Poc or mNOX-E36 for different time periods as indicated in 
uninephrectomized db/db mice (B) data represent means ± SEM from 5-7 mice, # p<0.05 compared 
to Poc-treated mice.  
 
4.2.1.8. Effect of CCL2 blockade on body weight and blood glucose 
Treatment with mNOX-E36 for different time lengths in uninephretomized db/db 
mice did not show and significant changes in body weight compared to the vehicle-
treated mice, which is an indirect indication of any changes in body physiology and 
food intake in treated mice. Some studies have shown a reduction in blood glucose 
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levels upon treatment with CCL2 antagonists, which was associated with increased 
insulin sensitivity in treated mice 174 (Figure 19).  
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Figure 19: Body weight and blood glucose levels. All animals were monitored through out the 
study period for any change in body weight (A) or blood glucose levels (B). Data is represented  
mean ± SEM (n = 9-12). 
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4.2.2. Effect of CCR2 and CCR5 dual antagonists in diabetic nephropathy 
 
4.2.2.1. Improvement of urinary albumin to creatinine ratio upon CCR2 and CCR5 
antagonism 
Albumin / creatinine ratio is an important clinical parameter for assessment of renal 
disease progression. In diabetic nephritis urinary albumin to creatinine ratio has been 
reported to increases with the progression of kidney inflammation. In our animal 
model of diabetic nephropathy we observed a trend in increase of urinary albumin to 
creatinine ratio over the time. To assess the effect of dual CCR2 and CCR5 blockade 
on the progression of disease we estimated urinary albumin to a creatinine ratio at 
different time points of the study.  
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Figure 20: Urinary albumin to creatinine ratio. Proteinuria was determined after every 2 weeks of 
CCR2 and CCR5 dual antagonists in uninephrectomized db/db mice treated as indicated. Data 
represent means of urinary albumin/creatinine ratio ± SEM (n = 9-12). 
 
 
Vehicle treated mice showed progressive increase in urinary albumin to creatinine 
ratio over the time. Treatment with orally active CCR2 and CCR5 dual antagonist 
WM 7671 and WM 7390 inhibited further increase in ratio over the duration of 
treatment. WM 7390 was found to be more potent to inhibit further increase. 
Although this was not statistically significant the trend in further growth was 
inhibited (Figure 20).  
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4.2.2.2. Effect of CCR2 and CCR5 dual antagonists on the macrophages 
Mac2 being a pan marker for macrophages in order to assess number of infiltrated 
macrophages in different compartments of kidney we employed Mac2 staining of 
paraffin-embedded kidney sections. Numbers of Mac2-positive cells were counted 
manually as described in materials and methods.  
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Figure 21: Mac2 staining of renal sections. Renal sections from 24 week old mice with or without 
uninephrectomy were stained for Mac2. A: Graphs show the numbers of Mac2 positive cells in 15 
glomeruli of different groups treated with vehicle of dual antagonists as indicated. B: Graph shows 
the number of Mac2 positive cells in interstitium (in 10 non overlapping high power fields) animal 
treated with vehicle or either of the dual antagonists as indicated at 6 months of age. ** p < 0.01 
verses vehicle treated 1K db/db mice. C: Representative renal sections from 24 weeks old 1K db/db 
mice stained for Mac2 (magnification 400X). 
 
We observed a significant reduction in number of Mac2-positive cells in glomeruli 
as well as in the interstitium in mice groups treated with WM 7671 and WM 7390 as 
compared to vehicle treated group. The percentage reduction of macrophage 
infiltration in glomeruli and interstitium upon treated with either of the two dual 
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antagonists (WM 7671 or WM 7390) was not more than 50 %, which was observed 
on blocking CCL2 alone (Figure 21).  
 
4.2.2.3. Effect of CCR2 and CCR5 dual antagonists on glomerulosclerosis 
Glomerulosclerosis was assessed in kidney sections from all groups using PAS stain 
as described. Glomeruli were scored manually in each sections and percentage of 
glomeruli with respective scores in each group are presented. Mean percentage of 
glomeruli with higher scores were significantly reduced upon treatment with WM 
7671 or WM 7390 in uninephrectomized db/db mice as compared to vehicle treated 
mice. Both antagonists significantly improved glomerulosclerosis (Figure 22).  
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Figure 22: PAS staining for renal sections. Renal sections from mice of all groups treated with 
either of the dual CCR2 CCR5 dual antagonists as indicated were stained with PAS and scored for 
evaluation of glomerulosclerosis (as described in methods). A: The graph illustrates the mean 
percentage of each score ± SEM from all mice in each group (n=10) *p<0.05 versus vehicle treated 
mice. B: Representative images from different groups at the age of 24 weeks stained for PAS 
(magnification 400X). 
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4.2.2.4. Effect of CCR2 and CCR5 dual antagonists on tubular pathology 
Improvement of tubular damage was assessed in treated db/db mice, by 
morphometry analysis of silver stains from paraffin-embedded kidney sections. 
Morphometry was performed using a 100 grid point assessment of each section. 
Numbers of cells beneath each grid point were classified in one of the four classes 
as: tubular cell damage, tubular dilatation, interstitial volume or collagen deposition. 
Mean percentage of cells for each of the four classes were counted and presented as 
mean ± sem. We did not observe any significant effect upon on treatment (with 
either of the antagonists tested) on tubular cell damage in compared to vehicle 
treated group (Figure 23).  
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Figure 23: Silver staining of renal sections. Silver staining of all renal sections form all groups was 
performed. Tubular pathological changes were evaluated using morphometric analysis of these renal 
sections as described in methods. A: Graph represents percentage means of cells for respective 
pathological index as indicated in graph. B: Representative images of renal sections from different 
animal groups. The data represent means ± SEM of the respective index from 9-12 mice in 
uninephrectomized (1K) db/db mice.  
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4.2.2.5. Effect on body weight and blood glucose 
Treatment with CCR2 and CCR5 dual antagonists (WM 7671 and WM 7390) in 
uninephretomized db/db mice for four weeks did not show any significant changes 
in body weight and blood glucose levels compared to the vehicle treated mice 
(Figure 24).   
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Figure 24: Body weight and blood glucose levels. All animals were monitored through out the 
study period for any change in body weight (A) or blood glucose levels (B). Data is represented as 
mean ± SEM (n = 9-12). 
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4.3. Inhibition of the homeostatic chemokine CXCL12 in diabetic nephropathy  
 
4.3.1. Plasma levels of CXCL12 
To achieve CXCL12 antagonism we used a RNA-aptamer (Spiegelmer mNOX-
A12), developed by NOXXON Pharma (Berlin). This RNA-aptamer binds to the 
active site of CXCL12 and makes its biologically non-functional CXCL12 bound to 
Spiegelmer remains in circulation. To asses the efficiency of the employed 
Spiegelmer for its biological activity we estimated CXCL12 levels in serum from all 
groups using Elisa. Serum levels of CXCL12 were significantly (p < 0.05) increased 
in mice treated with mNOX-A12 compared to vehicle of revmNOX-A12 treated 
mice at 6 months of age, indicating that CXCL12 specific Spiegelmers retain 
CXCL12 in the intravascular compartment (Figure 25). This finding is consistent 
with our previous observations with other Spiegelmers and indicates that the 
CXCL12 antagonist retains CXCL12 in the circulation 61.  
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Figure 25: Serum CXCL12 levels. Serum CXCL12 levels were determined by Elisa in 6 months 
uninephrectomized (1K) db/db mice upon treatment with active spiegelmer of control spiegelmer 
(n=10-12 in each group). Data are means ± SEM, *** p < 0.001 versus revmNOX-A12.  ND; not 
detected.  
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4.3.2. CXCL12 blockade prevents proteinuria in db/db mice 
In diabetic nephropathy glomerular pathology is usually associated with increasing 
levels of proteinuria indicative of progressive structural damage at the glomerular 
filtration barrier 6. Thus, the beneficial effect of CXCL12 blockade on glomerular 
structure should be associated with less proteinuria. To evaluate any effect of 
CXCL12 on improvement of progression of diabetic nephropathy 
albumin / creatinine ratio was determined at different time points of the study. 
mNOX-A12 but not the revmNOX-A12 Spiegelmer or vehicle prevented the 
progressive increase of urinary albumin/creatinine ratio in db/db mice (Figure 26). 
Thus, CXCL12 inhibition improves glomerular pathology and proteinuria in db/db 
mice.  
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Figure 26: Urinary albumin to creatinine ratio. Proteinuria was determined after every 2 weeks of 
CXCL12 antagonist administration in uninephrectomized db/db mice treated as indicated. Data 
represent means of urinary albumin/creatinine ratio ± SEM, * p < 0.01 versus vehicle treated 1K 
db/db mice (n = 9-12). 
 
 
4.3.3. Effect of CXCL12 blockade on glomerulosclerosis in db/db mice 
To test if CXCL12 blockade affects glomerular pathology in db/db mice, we 
initiated subcutaneous injections with anti-CXCL12 or control Spiegelmer (50 
mg/kg, every alternate day) at an age of 4 months in uninephrectomized db/db mice. 
Injections were continued for 8 weeks. Renal histomorphology in 6 months old 
db/db mice showed moderate glomerulosclerosis as compared to age-matched wild-
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type mice which was aggravated to diffuse glomerulosclerosis by early 
uninephrectomy of db/db mice (Figure 27). CXCL12 inhibition reduced the extent 
of glomerulosclerosis in uninephrectomized db/db mice to the level of age-matched 
sham-operated db/db mice (Figure 27). The control Spiegelmer had no effect. Thus, 
CXCL12 blockade started at 4 months of age reduces diffuse glomerulosclerosis in 
uninephrectomized db/db mice at 6 months of age. 
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Figure 27: PAS staining for renal sections. Renal sections from mice of all groups treated with 
Cxcl12 antagonist as indicated were stained with PAS and scored for evaluation of 
glomerulosclerosis (as described in methods). A: The graph illustrates the mean percentage of each 
score ± SEM from all mice in each group (n=10) ** p <0.01, *** p < 0.01 compared to sham 
operated mice, # p <0.05, ### p <0.001 versus vehicle treated mice. B: Representative images from 
different groups at the age of 24 weeks stained for PAS (magnification 630X). 
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4.3.4. CXCL12 blockade and tubulointerstitial pathology in db/db mice 
Advanced diabetic nephropathy is also associated with progressive tubulointerstitial 
injury. We quantified tubular dilatation, tubular cell damage, and interstitial volume 
as markers of tubulointerstitial damage by blinded morphometry and the numbers of 
Ki-67 proliferative tubular cells and Meca32 positive peritubular capillary cross 
sections as markers of interstitial vascular pathology in db/db mice at 6 months of 
age. 1K db/db mice revealed significant changes in the numbers of Ki-67 
proliferative tubular cells and Meca32 positive peritubular capillary cross sections 
but not of tubular dilatation, tubular cell damage, and interstitial volume (Figures 28 
and 29). As such the histomorphological abnormalities of the tubulointerstitial 
compartment were rather mild in 1K db/db mice. However, CXCL12 blockade 
significantly increased the numbers of peritubular cross sections and improved the 
tubular cell damage score but not up to the level of 2K wild-type mice (Figures 28 
and 30). Control Spiegelmer was ineffective in this regard. CXCL12 blockade, 
however, did not significantly affect any of the other histomorphological parameters 
of tubulointerstitial damage (Figure 28). Thus, CXCL12 blockade significantly 
improves tubular cell damage and the peritubular vasculature density in db/db mice. 
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Figure 28: Silver staining for renal sections. Silver staining of all renal sections form all groups 
treated with either vehicle or Cxcl12 antagonist was performed. Tubular pathological changes were 
evaluated using morphometric analysis of these renal sections as described in methods. A: Graph 
represents percentage means of cells for respective pathological index as indicated in graph. The data 
represent means ± SEM of the respective index from 9-12 mice in group.  
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Figure 29: Ki 67 staining of renal sections. Ki 67 staining of all renal sections form all groups 
treated with either vehicle or Cxcl12 antagonist was performed. Proliferating glomerular and 
interstitial cells were counted manually by in renal sections as described in methods. A: Graph 
represents mean number of Ki67 positive cells in glomeruli (A) and interstitium (B) as indicated in 
graph. The data represent means ± SEM of the respective index from 9-12 mice in group. C: 
Representative images of renal sections from different animal groups (magnification 400X). 
 
 
 
Sufyan G. Sayyed 76
Chemokines and Diabetic Nephropathy 
 
A
0
20
40
60
80
Wild type
db/db 2K
Vehicle
revmNOX-A12
mNOX-A12
*
M
ec
a 
32
 p
os
iti
ve
 c
el
l /
 H
PF
M
ea
n 
± 
SE
M
 (n
 =
 9
-1
2)
 
 B
 Sham (2K) Vehicle (1K) revmNOX-A12 mNOX-A12  
Figure 30: Meca32 staining of renal sections. Meca32 staining of all renal sections form all groups 
treated with either vehicle or Cxcl12 antagonist was performed. Number of Meca32 positive 
capillaries in each renal section was counted as described in methods. A: Graph represents percentage 
means of Meca 32 positive capillaries in respective groups as indicated in graph. The data represent 
means ± SEM of the respective index from 9-12 mice in group. B: Representative images of renal 
sections from different animal groups (Magnification 400X). 
 
 
4.3.5. Effect of CXCL12 blockade on infiltrating macrophages in 1K db/db mice 
Chemokine-mediated glomerular pathology in db/db mice can be mediated by 
macrophage recruitment 61, 96. To evaluate whether beneficial effect on renal 
physiology and histomorphological changes in kidney upon CXCL12 inhibition was 
associated with macrophage infiltration? we therefore evaluated the number of 
glomerular macrophages by immunostaining for Mac2. Mac2-positive cells were 
virtually absent in glomeruli of 2K wild-type mice but were increased in vehicle-
treated 1K db/db mice (Figure 31). Neither revmNOX-A12 nor mNOX-A12 
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Spiegelmer injections affected the number of Mac2 positive cells in glomeruli of 1K 
db/db mice (Figure 31). Thus, CXCL12 blockade prevents glomerular pathology and 
dysfunction in db/db mice independent of infiltrating glomerular macrophages.  
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Figure 31: Mac2 staining for renal sections. Renal sections from 24 week old mice with or without 
uninephrectomy were stained for Mac2. Graphs show the number of Mac2 positive cells in 15 
glomeruli of different groups treated with vehicle or CXCL12 antagonist as indicated at 6 months of 
age. * p < 0.05 compared to wild type 2K mice, # p< 0.05 compared to sham operated mice.  
 
4.3.6. Effect of CXCL12 blockade on stem cell mobilization 
CXCL12 has been reported to be involved in homing and migration of stem cells to 
different compartments in the body. Its role in migration of CXCR4 positive stem 
cells after acute kidney injury is well documented. We tried to evaluate if the 
beneficial effect observed upon treatment with CXCL12 antagonist are associated 
with stem cell mobilisation and tissue repair. We performed FACS analysis for cKit 
and Sca double positive cells in bone marrow, peripheral blood and kidneys isolated 
from all groups at the end of treatment. Similarly numbers of CXCR4 positive cells 
were analyzed.  
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Figure 32: FACS analysis of bone marrow, blood and kidney cell preparations. FACS analysis 
for cKit and Sca double positive stem cells and CXCR4 positive cells in bone marrow, circulating 
blood and kidney performed 3hr post last administration of CXCL12 antagonist. For each sample 
50,000 events were counted.  Graphs represents the mean percentage of events for each group (A) 
cKit and Sca double positive cells in bone marrow,   (B) cKit and Sca double positive cells in 
circulating blood, (C) cKit and Sca double positive cells in kidney, (D) CXCR4 positive cells in bone 
marrow, (E) CXCR4 positive cells in circulating blood and (F) Cxcr4 positive cells in kidney. Data 
represented as mean ± SEM (n =5-7), * p<0.05 compared to vehicle treated group. 
 
 
We found ckit and sca double positive cells in bone marrow were significantly less 
in mice treated with CXCL12 antagonist compared to vehicle treated, at the same 
time there was not much significant difference in the number of ckit and Sca double 
positive cells in peripheral blood and kidney in all groups. Similarly, the number of 
CXCR4 positive cells in bone marrow was significantly lower in mice treated with 
CXCL12 antagonists compared to vehicle treated group. At the same time we did 
not observe any change in the number of CXCR4 positive cells in kidney samples. 
Thus, the observed beneficial effects of CXCL12 antagonist are independent of stem 
cell recruitment into kidney (Figure 32).  
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4.3.7. Effect of CXCL12 blockade on macrophage polarization in kidney 
Beneficial effects observed upon CXCL12 antagonist administration in db/db mice 
were independent of number of infiltrating macrophages in kidney. Macrophage 
activation and polarization is now being extensively studied. Macrophage 
polarization as classically activated (class I) macrophages which mainly contributes 
to inflammatory processes on the other hand alternatively activated macrophages 
(class II) are mainly responsible for tissue repair. Thus, to evaluate the effects of 
CXCL12 antagonism modulation on macrophage polarisation we performed RT-
PCR from RNA isolated from whole kidney, for different macrophage phase 
markers including Arg1, MRC1 and MRC2, YM1 and iNos. Our results show over-
expression of class I markers like iNOS at the same time markers for alternative 
(Class II) activation were also up-regulated upon treatment. Thus, CXCL12 
blockade induced mixed population of renal macrophages characterised by class I as 
well as class II markers (Figure 33).  
 
0
2.0×10-6
4.0×10-6
6.0×10-6
8.0×10-6
Vehicle
revmNOX-A12
mNOX-A12
**
A
M
sr
1 
m
R
N
A
 e
xp
re
si
on
/1
8S
 r
R
N
A
ex
pr
es
si
on
 le
ve
l, 
M
ea
n 
 S
EM
0
5.0×10-7
1.0×10-6
1.5×10-6
2.0×10-6
2.5×10-6
Vehicle
revmNOX-A12
mNOX-A12
***
M
rc
1 
m
R
N
A
 e
xp
re
si
on
/1
8S
 r
R
N
A
ex
pr
es
si
on
 le
ve
l, 
M
ea
n 
 S
EM
B
0
2.0×10-6
4.0×10-6
6.0×10-6
8.0×10-6
Vehicle
revmNOX-A12
mNOX-A12
M
rc
2 
m
R
N
A
 e
xp
re
si
on
/1
8S
 r
R
N
A
ex
pr
es
si
on
 le
ve
l, 
M
ea
n 
 S
EM
C
0
5.0×10-7
1.0×10-6
1.5×10-6
2.0×10-6
2.5×10-6
Vehicle
revmNOX-A12
mNOX-A12
***
D
Ym
1 
m
R
N
A
 e
xp
re
si
on
/1
8S
 r
R
N
A
ex
pr
es
si
on
 le
ve
l, 
M
ea
n 
 S
EM
0
2.0×10-6
4.0×10-6
6.0×10-6
8.0×10-6
Vehicle
revmNOX-A12
mNOX-A12
***
iN
O
S 
m
R
N
A
 e
xp
re
si
on
/1
8S
 r
R
N
A
ex
pr
es
si
on
 le
ve
l, 
M
ea
n 
 S
EM
E
0
5.0×10-6
1.0×10-5
1.5×10-5
2.0×10-5
2.5×10-5
Vehicle
revmNOX-A12
mNOX-A12
**
F
A
rg
 I 
m
R
N
A
 e
xp
re
si
on
/1
8S
 r
R
N
A
ex
pr
es
si
on
 le
ve
l, 
M
ea
n 
 S
EM
                
Figure 33: Macrophage marker expression profile in kidney. mRNA expression for different 
classically activated macrophage (Class I) and alternatively activated macrophage (Class II) markers, 
Msr1(A); Mrc1 (B); Mrc2 (C); Ym1 (D); iNOS (E) and Arg1 (F) were evaluated in whole renal RNA 
preparations form all mice groups treated either with vehicle of CXCL12 antagonist. Expression level 
for each gene was normalized with 18S rRNA expression level of the respective sample. Data 
represented as mean ± SEM (n = 3-5), ** p<0.01, ***p<0.001 compared to vehicle treated group. 
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4.3.8. CXCL12 is mainly produced by podocytes in db/db mice 
We questioned whether CXCL12 is expressed in kidneys of db/db mice and first 
analyzed CXCL12 mRNA expression using RT-PCR in db/db mice kidney. 
CXCL12 mRNA was detectable in renal cortex preparations from 6 week old db/db 
mice (Figure 34). The renal CXCL12 mRNA levels did not significantly differ from 
those of sham-operated or uninephrectomized 6 months old db/db mice (Figure 34). 
CXCL12 immunostaining was positive in collecting ducts at the renal papilla, the 
uroepithelium along the renal pelvis, and in endothelial and smooth muscle cells of 
intrarenal vessels (Figure 35). In the renal cortex CXCL12 staining was also 
detected in glomeruli of 6 week old db/db mice. At higher magnification the 
glomerular staining originated from the cells on the outside of the glomerular 
capillaries, i.e. the visceral epithelial cells or podocytes (Figure 35). Co-staining 
with flurochrome-labelled antibodies against CXCL12 and WT1 confirmed 
podocyte-specific CXCL12 expression in glomeruli and excluded that CXCL12 
expression in mesangial cells (Figure 36). Six months old uninephrectomized db/db 
mice with type2 diabetes revealed the identical CXCL12 staining pattern and 
staining intensity as compared to 6 week old 2K db/db mice (Figure 35). Thus, 
podocytes are the major source of CXCL12 expression in glomeruli of db/db mice. 
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Figure 34: The mRNA expression levels of CXCL12. The mRNA expression levels of CXCL12 
were quantified by real-time RT-PCR and corrected for respective 18s rRNA levels. The data shown 
are means ± SEM (n = 3-5).  
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Figure 35: CXCL12 stains of renal sections at different age. Paraffin-embedded renal sections 
from kidneys of 6 week old 2K db/db mice and 6 months old 1K db/db mice were stained for 
CXCL12 and shown at three different magnifications. 10x/upper panel: renal medulla, papilla, and 
pelvis. 100x/middle panel: renal cortex, 1000x/lower panel: single glomeruli. Arrows indicate 
positive staining signals in visceral glomerular epithelia, i.e. podocytes. The images are representative 
for 8-12 mice in each group. 
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Figure 36: Fluorescence microscopy on renal sections. Fluorescence microscopy on renal sections 
of 6 months old db/db mice using a PE-labeled antibody for WT1 identified podocytes by red nuclear 
staining and using a FITC-labeled anti-CXCL12 antibody identified CXCL12 expression by green 
cytoplasmic staining (A, x400). At higher magnification (x1000) DAPI stains nuclei in blue (B) of 
which only few represent WT1 positive podocytes (C and D). Co-staining for CXCL12 (E) 
demonstrates that CXCL12 is present in the cytoplasm of podocytes with WT1 positive nuclei (F). 
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4.3.9. Effect of CXCL12 blockade on podocytes in glomeruli 
Implication of podocyte loss in development of diabetic nephropathy is well 
established and is correlated to the proteinuria. We quantified WT1 positive cells in 
glomeruli of each group. Number of WT1 (specific protein markers for podocytes) 
positive cells were significantly increased in group of mice treated with mNOX-A12 
compared to vehicle of control spiegelmer treated animals (Figure 37). 
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mNOX-A12 revmNOX-A12Vehicle
Figure 37: WT1 positive cells on glomerular tuft and in periphery. A: Graph showing mean 
number of WT1 positive cells on glomerular tuft. B: Graph showing mean number of WT1 positive 
cells in kidney present on cells other than glomerular tuft including parietal epithelial cells (PEC) and 
on vascular pole (VP). C: representative images of kidney sections stained for WT1. Images are 
representative of 8-10 mice from each group (400x). *p<0.05 compared to vehicle treated mice.  
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4.3.10. Effect of CXCL12 blockade on body weight and blood glucose 
Treatment with CXCL12 antagonists (mNOX-A12) in uninephretomized db/db mice 
for eight weeks did not show any significant changes in body weight and blood 
glucose levels compared to vehicle or revmNOX-A12 treated mice (Figure 38).   
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Figure 38: Body weight and blood glucose levels. All animals were monitored through out the 
study period for any change in body weight (A) or blood glucose levels (B). Data is represented as 
mean ± SEM (n = 9-12). 
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5. Discussion 
Several experimental animal models have been proposed for diabetic nephropathy, 
but none of these animal models represent chronicity which can mimic the advanced 
stage of human DN. In the current study we used genetically-induced type 2 diabetic 
(db/db) mice as mouse model of diabetic nephropathy. We performed 
uninephrectomy in these mice at early age (6 weeks) to aggravate the progression of 
diabetic nephropathy. All animal studies were terminated at 6 months of age of 
mice, which is relatively most chronic amongst the all animal models being used for 
diabetic nephropathy research. The histomorphological changes observed in 
uniphrectomised db/db mice were similar to the Kimmelstiel-Wilson lesions 
observed in human renal biopsies from patients with diabetic nephropathy. In 
addition increased mesangial cell proliferation and GBM expansion was observed in 
db/db mice and was aggravated upon uninephrectomy in these mice.  
Diabetic nephropathy in humans is characterized by microalbuminurea and 
progressive decline in GFR which was also observed in our animal model and was 
associated with increased infiltration of macrophage in glomeruli and interstitium. 
Thus, uninephrectomised db/db mice represent an acceptable animal model for 
diabetic nephropathy. 
 
5.1. Role of pro-inflammatory chemokines in diabetic nephropathy  
The development and progression of diabetic nephropathy is considered to be 
multifactorial. Many pathomechanisms have been postulated to contribute to the 
development and progression of diabetic nephropathy, but the involvement of 
inflammation in diabetic nephropathy is relatively new and an emerging field of 
research. Macrophage and monocyte (M/M) infiltration is hallmark of renal 
inflammation and is a major factor contributing towards the development and 
progression of diabetic nephropathy. CCL2 is a chemoattractant chemokine which is 
mainly responsible for M/M recruitment into different renal compartments in animal 
models of diabetic nephropathy as well as in humans 61, 91, 106, 175. One of the studies 
with CCL2 deficient mice has reported protection of glomerular pathology upon 
streptozotocin induced diabetes in these mice 95. A similar study has reported 
development of diabetic nephropathy to be significantly inhibited in CCL2 deficient 
db/db type II diabetic mice 96. In a previous studies from our lab we observed a 
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significant reduction in the number of glomerular macrophages with associated 
protection from glomerulosclerosis and proteinuria in db/db mice upon late onset of 
CCL2 blockade, which was started at 4 month till 6 month of age. In this particular 
study we observed up to 40 % reduction in glomerular and interstitial macrophages 
61. We hypothesized that earlier CCL2 blockade, may further reduce macrophage 
infiltration and may show more beneficial effects in improving diabetic 
glomerulosclerosis. In the present study we evaluated the effects of CCL2 blockade 
started at different stages of disease progression using a Spiegelmer (mNOX-E36) in 
db/db mice. Animals underwent uninephrectomy at early age (6 weeks) which 
aggravates disease progression in db/db mice. To evaluate effect of CCL2 blockade 
at different stages of diabetic nephropathy, treatment with CCL2 antagonist, mNOX-
E36 (50 mg/kg, s.c.) was started at 3 months, 4 months or 5 months of age and was 
continued till 6 months of age. Starting CCL2 blockade at different stages of disease 
progression resulted in reduced numbers of infiltrating macrophages in glomeruli as 
well as interstitium, which was consistent with our earlier report 61. Reduced 
macrophage infiltration was associated with improved glomerulosclerosis compared 
to vehicle-treated group. In addition treatment with the CCL2 antagonist resulted in 
significant improvement of glomerular filtration rate and albuminuria. The numbers 
of glomerular proliferating cells in glomeruli were also reduced upon CCL2 
antagonist administration which can be attributed to reduced macrophage- dependent 
mesangial cell proliferation and glomerular inflammation 73. Observed improvement 
of glomerular pathology and GFR in mice treated with CCL2 antagonist was 
consistent with our previous report and is further supported by earlier studies 95, 96. 
Interestingly, infiltration of glomerular and interstitial macrophages was inhibited to 
a similar extent in all treatment groups, and was independent of the treatment 
duration. Similarly, improvement of GFR and inhibition of albuminuria and 
glomerular cell proliferation was observed to be independent of the treatment 
duration. We did not observe any changes in blood glucose levels of mice treated 
with CCL2 antagonist compared to vehicle treated mice, which does not support the 
published study 174 the possible justification can be the age at which mice are treated 
with CCL2 antagonist. The results of this study have confirmed the involvement of 
CCL2-mediated macrophages recruitment in development and progression of 
diabetic nephropathy. CCL2 blockade initiated at an early stage of disease 
progression failed to show any further reduction in infiltrating macrophages over the 
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late onset of blockade which does not support our hypothesis of further reduction of 
infiltrating macrophages upon CCL2 blockade at earlier stage of diabetic 
nephropathy. The results of the study suggest involvement of other chemokine-
chemokine receptor in addition to CCL2-mediated macrophages recruitment.  
   
Thus, we further hypothesized that targeting more than one chemokine or 
chemokine receptors simultaneously may show some additive or synergistic effects 
in ameliorating the disease progression compared to single chemokine antagonism. 
There are several more chemokine-chemokine receptors that have been reported to 
be altered in experimental diabetic nephropathy as well as in clinical kidney biopsies 
from diabetic patients. CCR2 acts as receptor for many chemokines including CCL2, 
CCL13, CCL7 and CCL8 and is mainly expressed on monocytes, basophils, 
memory T-cells and pDCs. Improvement of renal fibrosis 127, inhibition of 
macrophage trafficking 128 and improvement of glomerulonephritis 132 has been 
documented upon CCR2 antagonism. CCR5 acts as common receptor for CCL8, 
CCL4, CCL3 and CCL5. Antagonism of CCR5 was associated with decreased 
macrophage infiltration in glomerular compartment in addition to reduction in 
collagen IV deposition 123. A simultaneous involvement of CCR2 and CCR5 in 
progression of diabetic nephropathy has not been explored yet. In one of the studies 
CCR5 deficiency was found to be associated with counter upregulation of CCL3, 
CCL5 and CCR1 expression, unfortunately, this study did not report CCR2 
expression levels in these mice. Thus, CCR2 and CCR5 being most attractive targets 
for diabetic nephropathy we hypothesized simultaneous blockade of CCR2 and 
CCR5 may show additive beneficial effects in ameliorating diabetic nephropathy. To 
test this hypothesis we evaluated effects of two different CCR2 and CCR5 dual 
antagonists in diabetic nephropathy using the same mouse model of diabetic 
nephropathy.  
 
Db/db mice underwent uninephrectomy at early age (6 weeks of age), and were 
treated with orally active CCR2 and CCR5 dual antagonists for a duration of 4 
weeks starting from 20 weeks of age. Animal groups treated with dual antagonists 
showed inhibition of further increase in urinary albumin to creatinine ratio as 
compared to vehicle treated animals. This was associated with improved 
glomerulosclerosis. There was no significant improvement of tubular pathology, 
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treatment with CCR2 and CCR5 dual antagonists failed to show any improvement of 
tubular cell damage, tubular dilatation, interstitial volume or collagen deposition. 
The improvement of glomerulosclerosis and improvement of albuminuria was 
associated with reduced number of macrophage infiltration in glomeruli as well as in 
interstitium. Improvement of glomerular pathology and albuminuria can be 
attributed to inhibition of macrophage infiltration to the glomerular and interstitial 
compartments. Surprisingly observed reduction in macrophage infiltration upon 
treatment with dual antagonists was up to 40 %, which was similar to CCL2 
blockade alone. These results suggested that targeting CCR2 and CCR5 
simultaneously in diabetic nephropathy had no additive effect over single CCL2 
blockade. CCL2 being ligand for CCR2 can mediate migration leuckocytes 
expressing CCR2 receptor which is mainly expressed by monocytes, memory T cells 
and pDCs 111. Basophils and memory T cells express CCR2 but not CCR5 on the 
other hand immature DC, Th 1 and T regulatory cells express CCR5 but not CCR2 
111. Thus, blocking CCR2 and CCR5 simultaneously can further inhibit the 
migration of Th 1 and T regulatory cells in addition compared to CCL2 blockade 
alone. The results suggest development and progression of diabetic nephropathy is 
not affected significantly by Th 1 and T regulatory cells. Since the type II diabetic 
animal model used in the current study does not support the role of Th 1 and T 
regulatory cells in development of DN, further studies with type I animal models are 
required to support this finding. Th 1 and T regulatory cells have not been looked at 
is a lacuna in the current study.  Based on our results we can conclude that the 
similar set of population was affected upon either CCL2 blockade alone or CCR2 
and CCR5 dual blockade. Another possibility can be counter up regulation of some 
other chemokine or chemokine receptor in vivo upon simultaneous blockade of 
CCR2 and CCR5, which was not looked into at present. Further studies in this 
regard will be helpful in understanding the complex in vivo situation. Results of the 
study does not support our hypothesis of targeting more than one chemokine 
receptor being more beneficial in improving the disease, but the hypothesis can not 
be ruled out completely, as inhibition of some other pair or chemokine-chemokine 
receptors may still show more beneficial effects in ameliorating diabetic 
nephropathy.  
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5.2. Role of homeostatic chemokines in diabetic nephropathy 
CXCL12 is a crucial mediator in tissue repair in acute kidney injuries, cell survival 
and supports tissue reoxigenation and regeneration. On the other hand in chronic 
diseases like retinal angiogenesis or pulmonary tissue fibrosis CXCL12 is 
responsible for progression of disease. The available studies make us believe that 
CXCL12 medicated effects are tissue specific and are varied depending on the 
chronicity. Thus, known functions of CXCL12 do not allow to reliably predict its 
potential role in chronic glomerulopathies such as diabetic nephropathy. We 
hypothesised CXCL12 plays role in development and progression of diabetic 
nephropathy either beneficial or pathological. To evaluate possible involvement of 
CXCL12 in DN, db/db mice uninephretomised at early age (6 weeks) received 
subcutaneous injections with either control spiegelmer (revmNOX-A12) or CXCL12 
antagonist (mNOX-A12) every alternate day, started at 16 weeks of age till 24 
weeks of age. At the end of the study consistent exposure of CXCL12 antagonist 
was confirmed by significantly increased serum levels of CXCL12 in mice group 
treated with antagonist. In the present study, we observed that transient blockade of 
CXCL12 prevented the progression of glomerulosclerosis and proteinuria in type 2 
diabetes. Tubular cell damage was prevented upon CXCL12 blockade in 
uninephretomized db/db mice, while we did not observe any significant changes in 
interstitial volume and tubular lumen. Since db/db mice model do not exhibit severe 
tubulopathy, we can not conclude about effect of CXCL12 antagonism in tubular 
pathology. Since glomerular proliferating Ki 67 positive cells were not affected 
upon CXCL12 blockade, improvement of glomerular pathology and albumin urea 
can not be attributed to effect of CXCL12 on mesangial cell proliferation.  
 
In the present study we did not observe any changes in ckit and sca double positive 
stem cell population in kidney upon CXCL12 blockade. At the same time CXCR4 
positive cell population was also not altered in kidney. The total ckit and sca double 
positive stem cell population observed in kidney was very less (< 0.5 % of total cell 
population) which makes it difficult to relate any changes with stem cells 
contributing towards improvement of glomerulosclerosis. Although stem cell 
population was reduced in bone marrow we did not observed any changes in kidney. 
Thus we exclude possibility of observed beneficial effects as a consequence of stem 
cell mobilisation to kidney, which is further supported by recent study describing 
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haematopoietic stem cell mobilization is independent of CXCL12-CXCR4 axis in 
kidney 176.  
 
To explore other possible mechanisms involved in the glomerulosclerosis we looked 
at Mac2 staining from kidney sections from all groups. There were no significant 
differences between the groups for Mac2-positive cells within glomeruli, hence the 
observed beneficial effects upon CXCL12 blockade were independent of 
macrophage infiltration. As in recent past several studies have reported significance 
of macrophage polarisation in inflammation and disease progression. Classically 
activated macrophage (M1), have been reported to be pro-inflammatory and 
contributes towards inflammation on the other hand alternatively activated 
macrophages (M2) are reported to be anti-inflammatory, which has been confirmed 
recently in a in vivo study with SCID mice 177. To assess the effect of CXCL12 
blockade on infiltrated and resident macrophages in glomeruli, expression levels of 
different phenotype markers of class M1 and M2 were analysed using RT-PCR. In 
the present study we observed some of M2 class markers were significantly up-
regulated upon CXCL12 blockade at the same time expression levels of iNOS, 
which is class M1 marker was also enhanced. Sine we looked into the whole kidney 
RNA preparations making it difficult to interpret whether this altered macrophage 
function affected disease progression. Further studies on isolated system with 
advanced experimental tools may be helpful in understanding the role of CXCL12 in 
macrophage polarisation.  
 
The immunohistochemical analysis revealed constitutive expression of CXCL12 in 
podocytes of adult db/db mice, which was confirmed upon co-staining with WT1 (a 
specific podocyte marker). Our finding that adult C57BL/6 and db/db mouse 
kidneys express CXCL12 selectively in podocytes and not in any of the other 
glomerular cell types is consistent with a previous report that described glomerular 
CXCL12 expression in autoimmune-nephritic NZB/NZW F1 mice 154. However 
podocytes did not stain positive for CXCL12 in another study using female SCID 
mice 171. Podocyte CXCL12 staining was also absent in human renal biopsies from 
children with various inflammatory disease entities 145. Glomerular CXCL12 
staining was reported to localize to mesangial cells in healthy human kidneys 178. 
However, in this study the histomorphological illustrations are more consistent with 
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CXCL12 expression in podocytes rather than in mesangial cells. Furthermore, 
CXCL12 staining in adult human kidney shows prominent CXCL12 expression in 
podocytes only (S. Segerer personal communication). In db/db mice the podocyte-
specific expression of CXCL12 corresponds to the glomerular expression pattern of 
VEGF, another hypoxia-inducible factor-1 regulated pro-angiogenic factor with 
similar functional roles in angiogenesis and hypoxia control 179. Podocyte-derived 
CXCL12 and VEGF both regulates glomerular capillary formation during renal 
development 180, further suggesting a role for CXCL12 in regulating glomerular 
structure by glomerular cell-cell interactions. These data confirm the functional 
importance of podocytes in the progression of (diabetic) glomerular disease 96 and 
for the first time, demonstrate a pathogenic role of podocyte-derived CXCL12 in 
(diabetic) glomerulosclerosis. 
 
Outside the kidney CXCL12 produced by distinct cells create appropriate 
microenvironments for other cell-types. For example, in the bone marrow stromal or 
endothelial cell-derived CXCL12 creates a niche for haematopoietic stem cells 181-
183. The CXCL12-dependent mechanism creates the necessary microenvironment for 
tumor metastasis engraftment 184, 185, the homing of memory T cells to lymph nodes 
186 or the specific recruitment of bone marrow cells that orchestrate angiogenesis 187. 
Accordingly we found that the progression of kidney disease in db/db mice did not 
increase renal Cxcl12 mRNA expression levels. Renal CXCL12 immunostaining, 
although not being a reliable quantitative assessment of protein expression, did also 
not increase from young to older db/db mice. These expression data might suggest 
that glomerular CXCL12 is needed to maintain the glomerular structure in db/db 
mice and that blocking CXCL12 might have detrimental effects. However, it was 
recently shown that adding an anti-CXCL12-specific antibody to low cyclosporin-
treatment significantly reduced renal allograft glomerulosclerosis, as compared to 
cyclosporin mono-therapy in a Fischer 344 to Lewis rat chronic renal allograft 
nephropathy model 164. Unfortunately, glomerular CXCL12 immunostaining was not 
reported in this study but the authors referred to the CXCL12-mediated 
improvement of allograft glomerulosclerosis to reduce arteriolar intimal thickening. 
Balabanian, et al. documented podocyte CXCL12 expression in autoimmune-
nephritic NZB/NZW F1 mice and also reported less glomerular pathology and 
proteinuria upon CXCL12 blockade with a neutralizing antibody 154. This was 
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mainly attributed to the effects of CXCL12 blockade on systemic autoimmunity and 
immune complex disease, which does not reliably allow us to conclude on the local 
role of CXCL12 expression on glomerular pathology in this model. The type 2 
diabetic nephropathy model of db/db mice used in the current study is independent 
of systemic allo- or autoimmunity and is thought to represent tissue remodelling as a 
consequence of hyperglycemia and glomerular hyperfiltration 188. Hence, the 
preventive effect of CXCL12 blockade on glomerulosclerosis in db/db mice should 
largely relate to the effects of blocking CXCL12 at the glomerular level. This would 
argue for a novel pathogenic role of podocyte-derived CXCL12 in (diabetic) 
glomerulosclerosis. This, again, would be consistent with the role of VEGF in 
rodent diabetic nephropathy, as VEGF is also produced by podocytes, acts locally on 
the glomerular vasculature, and blocking VEGF reduces glomerular pathology and 
proteinuria in experimental diabetic nephropathy 23.  
Our study does not yet define the underlying maladaptive function of CXCL12 but 
we found that CXCL12 blockade was associated with higher podocyte numbers. The 
possible reasons for this observation might be increased regeneration of podocytes 
or decreased podocyte loss. This could either relate to less podocyte death or 
increased podocyte regeneration. We observed increased number of WT1 positive 
parietal epithelial cells in peripheral as well as on the vascular pole upon CXCL12 
blockade, in addition to increased number of podocytes on glomerular tuft. This 
observation is further supported by recent study from Appel et al. in which authors 
have reported parietal epithelial cell differentiation to podocytes 189.  Hence, 
CXCL12 may either regulate podocyte cell cycle or podocyte regeneration from 
parietal epithelial cells 189, 190. This will require a podocyte-specific knock-out of 
CXCL12 in diabetic mice and given the role of podocyte CXCL12 on renal 
development, this knock-out will need to be conditional.  
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6. Summary and conclusions 
The role of inflammation in development and progression of diabetic nephropathy 
was evident from macrophage infiltration and CCL2 up regulation in kidney. The 
progression of diabetic nephropathy can be inhibited with CCL2 antagonists like 
mNOX-E36. CCL2 inhibition started at different stages of the disease progression 
showed no additive effects. The maximum percentage reduction of infiltrating 
macrophages into kidneys of diabetic mice achieved was independent of the duration 
of blockade with CCL2 antagonist. Thus, from results of the current study an 
involvement of other chemokine-chemokine receptor systems in the progression of 
disease is evident.  
 
When two different chemokine receptors CCR2 and CCR5 were blocked 
simultaneously using dual antagonists (WM 7671 and WM 7390), we did not 
observe any further reduction in macrophage infiltration and improvement of 
glomerulosclerosis as compared to CCL2 chemokine blockade alone. Thus, targeting 
CCR2 and CCR5 simultaneously showed no additive advantage in improving 
diabetic nephropathy over CCL2 blockade.  
 
Blocking the homeostatic chemokine CXCL12 improved glomerular pathology and 
proteinuria in diabetic mice independent of macrophage infiltration. There was no 
significant change observed on tissue fibrosis upon treatment with CXCL12 
antagonist, which rules out the inhibition of bone marrow derived fibroblasts to the 
kidney. The analysis of different macrophage phenotype markers showed up 
regulation of M1 as well as M2 macrophages markers, making it difficult to interpret 
if the observed effects are result of macrophage polarisation. Immunohistochemistry 
showed consistent expression of CXCL12 in kidney, mainly by podocytes. CXCL12 
blockade resulted in increased number of WT1 positive podocytes which can be 
attributed either to less podocyte loss or regeneration of podocytes. These data for 
the first time demonstrate a pathogenic role of CXCL12 in (diabetic) 
glomerulosclerosis and we postulate that glomerular podocytes are an important 
source of this chemokine. 
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In the current studies with different chemokine antagonists we found inhibition of 
the pro-inflammatory chemokine CCL2 could inhibit progression of 
glomerulosclerosis and was associated with decreased infiltration of macrophages to 
the glomerular and interstitial compartments. Similar effects were observed upon 
simultaneous antagonism of CCR2 and CCR5. Beneficial effects upon simultaneous 
blockade of CCR2 and CCR5 were similar to that of CCL2 blockade and were 
associated with decreased number of infiltrating macrophages. On the other hand 
beneficial effects observed upon CXCL12 blockade were independent of 
macrophage infiltration and were associated with increased number of podocytes.  
 
Diabetic nephropathy is multifactorial and inflammation and podocyte injury are 
well established in its development and progression. Based on results of our study 
we may envision that targeting a pro-inflammatory chemokine (CCL2) and a 
homeostatic chemokine (CXCL12) simultaneously can be a better approach for 
treating diabetic nephropathy. To test this hypothesis will be one of our future goals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proposed line of 
treatments: 
 CXCL12-CXCR4 
axis (to preserve 
podocytes) 
 Macrophage 
infiltration inhibition 
(to limit glomerular 
inflammation) 
 
Current line of treatment: 
 Anti-hyperglycaemic agents 
 Anti-hypertensive agents 
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7. Zusammenfassung 
Die Rolle und Bedeutung der Entzüdungsreaktion bei der Entwicklung und 
Progression der Diabetischen Nephropathie wurde in dieser Arbeit an Hand der  
Makrophageninfiltration und CCL2-Genhochregulierung in der Niere dargestellt. 
Die Progression der Diabetischen Nephropathie kann durch CCL2-Antagonisten wie 
mNOX-E36 aufgehalten werden. Die CCL2-Antagonisierung in fortgeschrittenen 
Stadien der Erkrankung konnte keinen additiven Effekt des Pharmakons 
nachweisen. Die maximal erreichte Reduktion infiltrierender Makrophagen in 
Nieren diabetischer Mäuse war zudem unabhängig von der Dauer der CCL2-
Blockade. Somit kann aus den Ergebnissen dieser Arbeit geschlossen werden, dass 
eine Beteiligung anderer Chemokin-Chemokin-Rezeptor-Systeme bei der 
Progression der Diabetischen Nephropathie vorliegen muss. 
 
Bei gleichzeitiger Blockade der Chemokien-Rezeptoren CCR2 und CCR5 durch 
Verwendung der zweifach-Antagonisten WM 7671 und WM 7390 konnte keine 
vermehrte Reduktion der Makrophageninfiltration und auch keine Verbesserung des 
Grades der Glomerulosklerose im Vergleich zu der alleinigen CCL2-Blockade 
festgestellt werden. Somit erbrachte die gleichzeitige Blockade von CCR2 und 
CCR5 keinen zusätzlichen Vorteil zur Behandlung der Diabetischen Nephropathie 
durch CCL2-Antagonisierung.  
 
Die Blockade des Chemokins CXCL12 zeigte eine Verbesserung der glomerulären 
Pathologie sowie eine Reduktion der Proteinurie bei diabetischen Mäusen 
unabhängig der Makrophageninfiltration. Es konnte keine signifikante Veränderung 
der Gewebsfibrose durch die Behandlung mit einem CXCL12-Antagonisten 
nachgewiesen werden, was die Inhibierung von Fibroblasten, die aus dem 
Knochenmark stammen, ausschließt. Die Analyse verschiedener Makrophagen-
Phänotypen zeigte eine Hochregulierung von sowohl M1- als auch M2-
Makrophagen-Marker, was es somit schwierig macht, die gezeigten Effekte als 
Makrophagen-Polarisierung zu interpretieren. In der Immunhistochemie konnte eine  
konsistente Expression von CXCL12 in der Niere und vor allem in Podozyten 
nachgewiesen werden. Die Blockade von CXCL12 führte zu einer Vermehrung 
WT1-positiver Podozyten, was einerseits auf einen verringerten Verlust oder 
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andererseits auf eine verstärkte Regeneration der Podozyten zurückgeführt werden 
kann. Diese Daten demonstrieren erstmals die Bedeutung von CXCL12 in der 
Pathogenese der diabetischen Nephropathie und man kann postulieren, dass 
glomeruläre Podozyten eine wichtige Herkunftsquelle dieses Chemokins darstellen.  
 
In der aktuellen Studie mit verschiedenen Chemokin-Antagonisten konnte durch 
Inhibierung des proinflammatorischen Chemokins CCL2 die Progression der 
Glomerulosklerose verhindert werden, die mit verminderter Makrophageninfiltration 
im Glomerulus und Interstitium einherging. Ähnliche Effekte konnten mit der 
simultanen Blockade von CCR2 und CCR5 gezeigt werden. Positive Effekte der 
gleichzeitigen Antagonisierung von CCR2 und CCR5 waren gleich denen der 
CCL2-Blockade und  waren mit einer verringerten Anzahl infiltrierender 
Makrophagen assoziiert. Andererseits konnten positive Effekte durch die CXCL12-
Blockade nachgewiesen werden, welche unabhängig von der 
Makrophageninfiltration war und mit einer vermehrten Anzahl von Podozyten 
einherging.  
 
Die Pathogenese der Diabetischen Nephropathie ist multifaktoriell und 
Inflammation sowie Podozyten-Schaden  tragen sehr zum Verständnis der 
Entwicklung und Progression der Erkrankung bei. Basierend auf den Ergebnissen 
dieser Arbeit kann man sich vorstellen, dass die gezielte Pharmakotherapie durch 
gleichzeitige Antagonisierung des proinflammatorischen Chemokins CCL2 und des 
homeostatischen Chemokins CXCL12 eine bessere Lösung zur Behandlung der 
diabetischen Naphropathie bedeuten könne. Um diese Hypothese zu verifizieren 
bedarf es weitere Studien.  
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9. Abbreviations 
 
ACE   angiotensin converting enzyme  
AGEs   advanced glycation end products 
Ang II   angiotensin II 
AOP-RANTES RANTES receptor blocker 
AR   aldose reductase 
AT1R   angiotensin II type 1 receptor  
AT2R   angiotensin II type 2 receptor 
BM   basement membrane  
BSA   bovine serum albumin 
BUN blood urea nitrogen 
cDNA complementary DNA 
CCL2   chemokine C-C motif ligand 2 
CCL5   chemokine C-C motif ligand 5  
CCR1   chemokine C-C motif receptor 1 
CCR2   chemokine C-C motif receptor 2 
CCR3   chemokine C-C motif receptor 3 
CCR5   chemokine C-C motif receptor 5 
CCR7   chemokine C-C motif receptor 7 
CX3CL1  chemokine C-X3-C motif ligand 3  
CXCL10  chemokine C-X-C motif ligand 10  
CXCL12  chemokine C-X-C motif ligand 12 
CXCR2  chemokine C-X-C motif receptor 2 
CXCR4  chemokine C-X-C motif receptor 4 
CXCR7  chemokine C-X-C motif receptor 7 
CX3CR1  chemokine C-X3-C motif receptor 1 
CKD   chronic kidney disease  
CML   N-ε-carboxymethyllysine 
CT   cycle threshold 
CTGF connective tissue growth factor 
DAG diacylglycerol 
3DG 3-deoxyglucosone 
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DARC Duffy antigen receptor for chemokines 
DCCT Diabetes Control and Complication Trial 
ddH O double distilled water 2
DEPC diethyl pyrocarbonate 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO   dimethyl sulfoxide 
DN   diabetic nephropathy 
et al.   et alii = and others 
e.g. exempli gratia = for instance  
ECM   extracellular matrix 
EDTA   ethylendiamintetra acetic acid 
ELISA Enzyme-Linked Immunosorbent Assay 
ESRD end-stage renal disease 
ET endothelin 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
GBM   glomerular basement membrane 
GENC glomerular endothelial cell line 
GFR glomerular filtration rate 
GPCR   G protein-coupled receptor 
HE Hematoxylin-Eosin 
Hif hypoxia inducible factor 
HIV human immunodeficiency virus 
hpf high-power-field 
ICAM-1 intercellular adhesion molecule-1 
sICAM-1 soluble intercellular adhesion molecule-1  
i.e. id est = in other words 
IL interleukin 
IL-8   interleukin-8  
IFN- interferon- 
IP-10   interferoninducible protein-10  
J774   murine macrophage cell line 
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kDa kilo dalton 
K/DOQI  Kidney Disease Outcomes Quality Initiative 
MCP   monocyte chemoattractant protein  
MCP-1 monocyte chemoattractant protein-1 
MCP-2  monocyte chemoattractant protein-2 
Met-RANTES N-terminal with Methionin modified CCL5/RANTES 
MG   methylglyoxal 
min   minute/minutes 
MIP   macrophage inflammatory protein  
MIP-1 macrophage inflammatory protein-1 
ml/min   milliliter/minute 
M/M monocytes / macrophages 
mNOX-E36 anti-CCL2 Spiegelmer  
mNOX-A12 anti-CXCL12 Spiegelmer 
mRNA messenger ribonucleic acid 
MTC murine tubular cell line 
NADPH nicotinamide adenine dinucleotide phosphate 
n.d. nondeteclable 
NF-B nuclear factor-B 
NO   nitric oxide  
O.D.   optical density 
PAS Periodic acid Schiff  
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pDCs plasma dendritic cells  
PDGF platelet derived growth factor 
PGE2 prostaglandin E2 
PKC protein kinase C 
Poc scrambled sequence of RNA  
 (Control Spiegelmer for mNOX-E36) 
PPARs peroxisome proliferator-activator receptors 
PPAR-γ peroxisome proliferator activator receptor gamma 
RANTES regulated on activation normal T cell expressed and secreted  
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RAS renin angiotensin system 
revmNOX-A12 Control Spiegelmer for mNOX-A12 
RNA ribonucleic acid 
Rnase ribonuclease 
ROS   reactive oxygen species 
RPM   revolutions per minute 
RPMI Medium cell culture medium  
rRNA   ribosomal ribonucleic acid 
RT   room temperature 
RT-PCR real-time reverse transcription-polymerase chain reaction 
s    second 
SDF-1   stromal cell-derived factor-1  
SDH sorbitol dehydrogenase 
SMA smooth muscle actin 
STZ   streptozotocin 
TGF- transforming growth factor- 
Th1   T helper cell type 1 
TNF- tumor necrosis factor- 
TZDs   thiazolidinediones 
U   units 
UAE urinary albumin excretion 
UKPDS UK Prospective Diabetes Study 
UUO unilateral uretral obstruction  
VCAM-1 vascular cell adhesion molecule-1 
VEGF vascular endothelial growth factor 
vs versus 
v/v   volume/volume 
WM 7390  CCR2 and CCR5 dual atagonist 
WM 7671  CCR2 and CCR5 dual atagonist 
WT   wild type 
WT1   Wilms tumor  
1K   1 kidney 
2K   2 kidneys 
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Appendix 
1. FACS buffer :  
Sterile DPBS   500 ml 
Na Azide  500 mg (0.1 % ) 
BSA  1 g (0.2 %) 
2. Paris Buffer: 
20 mM Tris-HCL, 125 mM NaCl,  10 mM KCl, 10 mM Sodium 
acetate, 5 mM Glucose. 
For 1000 ml: 
Tris-HCL (MW 121.14)  2.4228 g 
NaCl (MW 58.44)   7.31 g 
KCl (MW 74.56)   0.74556 g 
Sod. Acetate (MW 82.03)  0.8203 g 
D-Glucose (MW 180.16)  0.9 g 
 
3. 10X HBSS (Hank’s Balanced Saline Solution) with Ca, Mg: 
  For 1000 ml 
  KCl   4 g 
KH2PO4  0.6 g 
NaCl   80 g 
Na2HPO4.2H2O 0.621 g 
NaHCO3  3.5 g 
CaCl2    1.4 g (or CaCl2.2H2O 1.854 g) 
MgCl2.6H2O  1 g 
MgSO4.7H2O  1 g 
D-Glucose  10 g 
Dissolve in 900 ml of distilled water and adjust to pH 7.4 with 1N HCl or 1N 
NaOH. Make up the volume with distilled water to 1000 ml. 
 
4. 10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg: 
  For 1000 ml 
  KCl   4 g 
  KH2PO4  0.6 g 
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  NaCl   80 g 
  Na2HPO4.2H2O 0.621 g 
Dissolve in 1000 ml and autoclave. 
 
5. DNAse stock solution (1 mg/ml): 
 DNAse (type III) 15000 U/6 mg (Sigma D5025) 
To prepared 1 mg/ml solution: Add 6 ml of 50 % (w/v) Glycerol in 20 mM 
Tris-HCl (pH 7.5), 1 mM MgCl2.  
Can be kept at – 20 0C for several weeks. 
Caution: Solution is stable only for 1 week at 4 0C. 
 
6. 50 % Glycerol in 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2: 
 a. 0.48 g of Tris-HCl in 100 ml of distilled water, adjust pH to 7.4 (= 40 
mM)  
 b. 50 ml of Glycerol 100 % + 50 ml of 40 mM Tris-HCl (20 mM) 
 c. Add 100 ul of 1M MgCl2 solution. 
 
7. Collagenase / DNAse solution: 
1 mg/ml Collagenase, 0.1 mg/ml DNAse in 1X HBSS (with Ca, Mg) 
For 10 ml: 
Collagenase (type I) (Sigma C0130)  10 mg 
1 mg/ml DNAse stock solution  1 ml 
HBSS (with Ca, Mg)    9 ml 
To be preheated in 37 0C water bath before use. 
Caution: Prepare freshly every time (Stable only for few days) 
 
8. Collagenase solution: 
1 mg/ml Collagenase in 1X HBSS (with Ca, Mg)  
 For 10 ml: 
 Collagenase (type I)   10 mg 
 HBSS (with Ca, Mg)    10 ml 
To be preheated in 37 0C water bath before use. 
Caution: Prepare freshly every time (Stable only for few days) 
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9. EDTA 2 mM: 
EDTA (MW  ) (Sigma) 
EDTA   7.44 mg in 10 ml HBSS (without Ca, Mg) 
To be preheated in 37 0C water bath before use. 
 
10. Anesthesia mixture 
10 ml Midazolam (1mg/ml)  
2 ml Fentanyl (0.05 mg/ml) 
1 ml Dormitor (1 mg/ml) 
 
11. Antagonist mixture 
5 ml Annexate (0.1mg/ml)  
0.5 ml Antisedan (5 mg/ml) 
3 ml Naloxon (0.4 mg/ml) 
 
12. MACS Buffer 
PBS pH 7.2 
0.5% bovine serum albumin 
2 mM EDTA 
  
13. Citrate buffer 10X 
110 mM Sodiumcitrate 
O  in ddH2
with 2N NaOH to pH 6  
 
14. PBS 
2.74 M NaCl 
54 mM KCl 
30 mM KH PO4 2
130 mM Na HPO4 2
O  in ddH2
with HCl to pH 7.5   
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